Myoadenylate deaminase deficiency by Sinkeler, S.P.T.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/113327
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.


Myoadenylate deaminase 
deficiency 
A study of its clinical significance 

Myoadenylate deaminase 
deficiency 
PROEFSCHRIFT 
ter verkrijging van de graad van Doctor in de Geneeskunde 
aan de Katholieke Universiteit te Nijmegen, 
op gezag van de Rector Magnificus 
Prof. Dr. B.M.F, van lersel 
volgens het besluit van het College van Decanen 
in het openbaar te verdedigen 
op vrijdag 23 januari 1987 
des namiddags te 1.30 uur 
door 
SIETZE PIETER TJALKE SINKELER 
geboren te Nijmegen 
Promotores: 
Prof. Dr. B.P.M. Schulte 
Prof. Dr. R.A. Binkhorst 
Co-referenten: 
Dr. E.M.G. Joosten 
Dr. T.L. Oei 
Dr. R.A. Wevers 
4 
Ter herinnering aan mijn vader, 
voor ma, Irene en Steef. 
5 
Contents 
ABBREVIATIONS 9 
GENERAL INTRODUCTION И 
CHAPTER I 
1.1. CLINICAL FEATURES IN MAD-DEFICIENCY 15 
1.2. MAD AND PURINE METABOLISM IN MUSCLE 17 
1.3. PURINE NUCLEOTIDE CYCLE 18 
1.4. SOME CHARACTERISTICS OF AMP DEAMINASE 22 
1.5. THE CONSEQUENCES OF MAD-DEFICIENCY 22 
1.6. SCREENING IN MAD-DEFICIENCY 23 
1.7. GENETICS 25 
1.8. THE INTENTS 25 
CHAPTER II 31 
THE RELATION BETWEEN BLOOD LACTATE AND AMMONIA IN 
ISCHEMIC HANDGRIP EXERCISE 
CHAPTER III 41 
IMPROVEMENT OF SCREENING IN EXERTIONAL MYALGIA 
WITH A STANDARDIZED ISCHEMIC FOREARM TEST 
CHAPTER IV 53 
ISCHAEMIC EXERCISE TEST IN MYOADENYLATE DEAMINASE 
DEFICIENCY AND McARDLE'S DISEASE: MEASUREMENT OF 
PLASMA ADENOSINE, INOSINE AND HYPOXANTHINE 
6 
CHAPTER V 59 
AMP DEAMINASE DEFICIENCY: STUDY OF THE HUMAN SKELETAL 
MUSCLE PURINE METABOLISM DURING ISCHAEMIC 
ISOMETRIC EXERCISE 
CHAPTER VI 71 
MYOADENYLATE DEAMINASE DEFICIENCY: A CLINICAL, 
GENETIC AND BIOCHEMICAL STUDY IN NINE FAMILIES 
CHAPTER VII 81 
MYOADENYLATE DEAMINASE DEFICIENCY: CAUSE OF 
EXERTIONAL MYALGIA OR INCIDENTAL FINDING? 
CHAPTER VIII 89 
CONCLUDING REMARKS AND APPENDIX 
SUMMARY 99 
SAMENVATTING 103 
PUBLICATIONS 107 
ACKNOWLEDGEMENTS 109 
CURRICULUM VITAE 111 
8 
ABBREVIATIONS 
adenosine deaminase 
adenosine 
adenosine diphosphate 
adenosine monophosphate 
adenosine monophosphate deaminase 
analysis of variance 
adenosine triphosphate 
creatine phosphate 
energy charge 
energy expenditure per unit of performance 
guanosine diphosphate 
guanosme triphosphate 
hypoxanthine 
inosine monophosphate 
inosine 
lactate 
myoadenylate deaminase 
maximal voluntary contraction force 
nicotinamide adenine dinucleotide 
ammonia 
purine nucleotide cycle 
succinyl adenosine monophosphate 
total adenine nucleotides 
total impulse 
9 
10 
GENERAL INTRODUCTION 
The enzyme myoadenylate deaminase (MAD), or skeletal muscle adenosine 
monophosphate deaminase (AMP-deaminase, AMPD), underwent a revival of inter­
est by an article of Fishbein1 in 1978 with the intriguing title: 'Myoadenylate de­
aminase deficiency: A new disease of muscle'. The author describes the discovery of a 
new disease by screening muscle biopsies with a new histo-enzymatic stain for MAD. 
Although the deficiency of the enzyme as such was described before,2 Fishbein 
associated it for the first time with the existence of myopathy in a causal relationship. 
Surprising is the suggestion that the deficiency state constitutes the most common 
enzyme deficiency of skeletal muscle!3 However, the complaints of this myopathy due 
to the absence of MAD are ill-defined and comprise exercise-induced easy fatigability, 
muscle-aches and -cramps. Although this exertional myalgia is a very common set of 
complaints in daily life and clinical practice, its causes arc infrequently satisfactorily 
captured. Besides, the existence of myoadenylate deaminase deficiency as a disease sui 
generis was questioned soon after the first report.4 
The high prevalence of the deficiency state and the possible causative relation 
with the commonly occurring complaints of exertional myalgia made it seem worth­
while to study the enzyme deficiency. In particular a screening test for the deficiency, 
evading the necessity of taking muscle biopsies, might be promising in resolving 
questions concerning the relation between the deficiency state and clinical com­
plaints. Additionally, the study of the consequences of MAD-dcficicncy on the purine 
metabolism and the energy economy of skeletal muscle might shed some light on the 
hitherto unrewarding attempts at solving the problem of muscle fatigue. 
In chapter I the aims of this thesis are outlined, preceded by a review of the 
literature relevant to the questions that have arisen. Their subsequent answers are 
formulated in six papers, which make up the chapters II to VII. The thesis is completed 
with a general discussion of the results obtained in the study (chapter VIII). 
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Chapter I 
INTRODUCTION AND OUTLINE OF INVESTIGATION 
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1.1. Clinical features in MAD-deficiency. 
The main clinical features reported in the first 5 patients with myoadenylate 
deaminase (MAD) deficiency as a disease state in itself, were rapid muscle fatigue, 
weakness and/or cramping following moderate to vigorous exercise,1 which have 
since then been confirmed repeatedly by the same and other authors.2,3'4 After the first 
description of these 5 deficient patients it became clear that this set of symptoms, 
commonly denoted as 'exertional myalgia', was not distinctive or characteristic: 
muscle weakness and fatigue can have a variety of causes ranging from disturbances in 
the central or peripheral nervous system to impaired function or destruction of the 
contractile machinery of skeletal muscle (Fig. I) . 5 
Figure 1. Cham of command for muscular contraction and the possible mechanisms underlying fatigue. 
(After R.H.T. Edwards, 1983)* 
Possible fatigue mechanism: 
'Psyche' 
Brain 
1 Impaired motivation i.e. neural motor 
« drive and motor unit recruitment 
Spinal Cord 
4 < Impaired reflex drive 
Peripheral Nerve 
4 < Impaired neuromuscular transmission 
Muscle sarcolemma 
1 « Impaired action potential 
Transverse tubular system < K+, Na*, Η,Ο imbalance 
1 < Impaired excitation 
C a " 
I < Impaired activation 
Ί· « Impaired energy supply 
Actin-myosin interaction 
I 
Cross bridge tension + heat < Thermal damage 
1 < Sarcomere damage 
Force output 
As can be seen in Figure 1, the command chain for voluntary muscular activity 
thus involves many steps and force failure - that is fatigue — may be due to a breaking 
of anyone of the links of the chain of command.6 When keeping in mind that ATP is 
the ultimate muscle energy source for contraction and the involvement of MAD in 
ATP-catabolism, one obviously starts looking for a possible relationship between 
muscle fatigue and a derangement, if any, in ATP metabolism in MAD-deficiency. A 
factor which hampers the description of the clinical picture is the frequent association 
of MAD-deficiency with other well-defined disorders, e.g. hypokalaemic periodic 
paralysis,7 amyotrophic lateral sclerosis,8 Kugelberg-Welander syndrome,8 pro­
gressive systemic sclerosis,9 dermatomyositis2 and so on. So far, for instance, there 
have been described, irrespective of our own cases, at least 95 patients with MAD-
deficiency, of which 50 were suffering from another disorder as well (see Table 1). So 
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there is no strongly suggestive constellation of signs and symptoms and most cases of 
the deficiency state are identified incidentally by routine application of the adenylate 
deaminase stain on muscle biopsies.10 
Table 1 Associated disorders in MAD di 
DiMauro et al " 
Engel et al 7 
hshbein et al ' ' 
Gertler et a l , 
Hayes et al 1^ 
Heffner et al » 
Joosten et al ,5 
Kar et al ' 
Kelemen et al 16 
Kelemen et al > 
Mercelis et al '" 
Rossi et al " 
Schölte et al " 
Shumate et a l я 
Nun-iber 
patients 
1 
1 
58 
1 
1 
6 
4 
6 
1 
6 
1 
1 
2 
6 
îficiency described 
of MAD deficient 
in literature 
Associated disorders (number of 
patients in parentheses) 
none 
Primary hvpokalaemic 
periodic paralysis (1) 
30 patients with a broad spectrum of 
other neuromuscular diseases 
systemic sclerosis (1) 
none 
collagen vascular disease (3) 
neuropathy (2) 
dermatomyositis (2) 
systemic sclerosis (1) 
none 
congenital myopathy (2) 
amyotrophic lateral sclerosis (1) 
facial and limb girdle myopathy 
none 
skeletal muscle type I atrophy and car-
diomyopathy (2) 
Kugelberg-Welander syndrome (1) 
amyotrophic lateral sclerosis (1) 
dystrophy (1) 
If one takes into account the clinical diversity of the patients with an associated other 
illness, it is not surprising that several authors have questioned the existence of M AD-
deficiency as a disease sui generis, suggesting that MAD-deficiency might not in itself 
produce symptoms, signs or complaints. The strongest advocates of this view are 
Shumate et al.820 but also Heffner14 and Hayes et al." can be classed with them. 
Shumate8 found on an initial screen of 256 biopsies 6 with absent enzyme activity. The 
clinical findings were so heterogeneous that they suggested MAD-deficiency was an 
incidental finding or produced symptoms only in concert with other, as yet unidenti-
fied, abnormalities or circumstances. The same argument was used by Heffner,14 who 
found 6 deficient patients out of a series of 249 unselected, consecutive muscle 
biopsies, but among these an undetermined number of patients with an exertional 
myalgia. Hayes et al. " emphasized the need to look for an additional metabolic defect 
in patients with MAD-deficiency on the basis of their findings in two brothers who 
had virtually identical clinical features of an exertional myalgia whereas only the elder 
brother lacked the enzyme. Although Hayes et al. do not refer to the possibility of 
heterozygosity in the symptomatic yet not deficient brother, this issue is open to 
debate as is suggested by Fishbein et al.21 We shall go into the matter of genetics later 
on. On the basis of the same arguments as brought forward by the preceding authors, 
Kelemen et al."" were inclined to be sceptical, but in the course of evaluating patients 
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with chronic exertional myalgia they biopsied 36 index patients, of which 3 (8.3%) 
lacked MAD. MAD-deficiency was much more common in patients with myalgia 
(8.3%) than in patients who underwent a muscle biopsy for other clinical problems 
(1.6%); hence their final remark that these findings seem to refute the view of 
Shumate et al. 
Summarizing the data in this paragraph: 
1. In MAD-deficiency there is no characteristic set of clinical signs or symptoms. 
I here are two major situations in which MAD-deficiency is discovered: in cases of 
myalgia where in the absence of other abnormalities the MAD-deficiency probably 
plays a causal role; and as an associated finding in the biopsy evaluation of other 
neuromuscular diseases. The question then arises, whether this association is 
simply coincidental or whether the deficiency occurs secondarily.I2 Furthermore, it 
stresses the need for a reliable, non-invasive screening test. 
2. The question has been put forward whether M AD-deficiency is a disease in itself or 
not. 
1.2 Purine metabolism and MAD in muscle. 
The prime function of muscle is to generate force.22 The performance of muscle 
was early recogm/ed te be dependent on energy derived from chemical reactions 
within the tissue.2' The transducer of chemical energy to mechanical work in muscle is 
adenosinetnphosphate (ATP). So ATP is the immediate source of energy for muscular 
contraction.2",'2S If energy is required, ATP is hydrolyzed to adenosinediphosphate 
(ADP) and adcnosinemonophosphate (AMP). This reaction is not dependent on 
oxygen. The ATP store, however, is in itself very limited and has to be continuously 
refilled.2|S I he sources for ATP-resynthesis are 1. breakdown of creatine phosphate 
(CP, the Lohmann reaction), 2. anaerobic glycogcnolysis, and 3. if oxygen is avail­
able, oxidation of pyruvate or fatty acids and oxydative phosphorylation in 
mitochondria2'' (Table 2). CP acts as a secondary energy store and provides a means 
for the immediate resynthesis of ATP.25 CP probably has its greatest importance for 
contraction during the first few seconds of increased energy demands before other 
energy-delivering systems (e.g. glycolysis) have had time to adapt. ATP is then very 
Table 2 tnergy sources for muscular activity (Reaction equations are not complete') 
Short term (anaerobic)sourccs 
creatmephosphate + ADP <—- creatine + ATP 
glycogen/glucose + ADP +P, > lactate + ATP 
Long term (aerobic)sources 
glycogen/glucose + ADP + P, + O, • Η,Ο + CO, + ATP 
fattv acids + ADP + P, + O, > Η,Ο + CO, + AIΡ 
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rapidly regenerated through the rephosphorylation of ADP by CP with the aid of 
creatinekinase.2" 
Interlude 1. 
Nucleotides i.e. the constituting elements of nucleic-acids, are composed of a 
purine- or pyrimidine base, a monosaccharide (nearly always nbose) and phosphoric 
acid. ATP is a purine nucleotide with the base adenine, the sugar nbose and 3 
phosphoric acid groups. ADP and AMP contain two and one phosphoric acid group 
respectively. Adenine (6-amino-purine) contains a cyclical structure which was called 
a purine ('purum uncum') because this cyclical structure is the basis skeleton for uric 
acid. 
Nucleosides are called the molecules which consist of a purine or pyrimidine base 
and a sugar, and carry trivial names corresponding to their base, which in the case of 
the purine nucleotides will end on -osin, e.g. for adenine the nucleoside's nomencla-
ture will be adenosine.2" 
Figure 2 shows a simplified scheme of purine nucleotide breakdown. 
The size of the total adenine nucleotide pool (TAN: ATP + ADP + AMP) can 
decrease under some physiological conditions, but this can only occur by the break-
down of AMP.26 Two separate pathways are possible (Fig. 2): deamination to 
inosinemonophosphate (IMP) or dephosphorylation to adenosine. In skeletal muscle 
deamination seems to be the main route, whereas in heart muscle both routes are 
available.29 Deamination of AMP and thus the liberation of ammonia, is catalyzed by 
MAD and is essentially an irreversible reaction. 
1.3. Purine nucleotide cycle. 
In the early twenties ammonia was one of the topics in physiology. Well known 
investigators as Parnas, Embden, Meyerhof, Lohmann and Meyer, among others, 
studied the production of ammonia and uric acid. Already two decades before, 
Richard Bunan10 demonstrated the connection between exercise and an increasing 
amount of uric acid excreted m the urine although he had no idea about its source. In 
1928 Embden3133 ascertained the relation between the formation of ammonia and 
muscular work, and recognized that ammonia production depends on the frequency 
of muscle stimulation: the higher the frequency the more pronounced the production. 
The ammonia produced was derived from an adenine nucleotide and Embden et al. 
succeeded in isolating this compound. Shortly thereafter Pamas"1 ^ confirmed these 
findings and was the first to perceive the possibility of muscle to resynthesize this 
adenine nucleotide r"·" ""mply by a reversal of the reaction but via, what he described 
as, a purine nucleotide ) cle ('Kreislauf der Purinnucleotide') ! He delineated the chain 
of reaction as follows: 
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1. contraction : adenine nucleotide > IMP + N H , 
2. at rest : IMP + O, + amino acid derivate X * AMP + deaminated 
product of X. 
\ 
S-AMP 
IMP - ^ . 
Myoadenylate 
deaminase 
Incisine ^ 
η 
Hypoxanthine 
Xanthine 
7 
NH, 
7 
NH, 
ATP 
AMP 
Ade 
ADP 
ьч 
ADP 
1 ' 
Uric acid 
Figure 2. Simplified scheme of purine nucleotide breakdown 
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The first step in the delineation of the purine nucleotide cycle (PNC, Fig. 3) was 
made by G. Schmidt,3" one of Embden's co-workers, in 1928. He succeeded in 
isolating MAD and drew the conclusion from his experiments that the formation of 
ammonia from AMP and adenosine (Fig. 2) involves two different deaminases, MAD 
and adenosinedeaminase (ADA). The other two en/ymes which together with MAD 
constitute the PNC, adenylosuccinate synthetase and adenylosuccinase, were identi­
fied in 1955. ,й 
GDP 
Aspartate 
+ _ -^r Adenylo-
GTP . ^ ^ Succinate 
Synthetase 
S-AMP 
Adenylosuccinate 
Lyase 
Adenylate deaminase 
Himaratc 
IMP - * -
Τ 
AMP 
NH, 
big J Purine Nucleotide Cycle 
The PNC appeared again before the footlights by the elaborate studies of Lowenstein 
et al.19 They proposed the following functions for this cycle: 
1. regulation of the relative levels of the adenine nucleotides AMP, ADP and ATP. 
Conversion of AMP to IMP by MAD leads to the formation of ATP from ADP by a 
readjustment of the adenylate kinase (myokinase) equilibrium: 2 ADP-^l ATP + 
1 AMP. In this way it serves to maintain a high ATP/ADP ratio. 
2. liberation of ammonia from amino acids via aspartate, which thereby makes 
available the carbon skeletons of amino acids for energy production. A combina­
tion of the reactions catalyzed by the enzymes of the PNC and by fumarase, malate 
dehydrogenase and phosphoenolpyruvate carboxykinase leads to the conversion 
of aspartate to phosphoenolpyruvate, which can then be oxidized completely. 
3. adjustment of the levels of citric acid cycle intermediates. 
4. control of phosphofructokinase and hence of glycolysis; this is achieved via effects 
on the levels of AMP and, possibly, of ammonia, both of which are activators of 
the enzyme. 
5. regulation of Phosphorylase b by accumulation of IMP, an activator of the enzyme 
under conditions when AMP is low and Phosphorylase exists largely in the b form. 
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Ad 1. 
The relative levels of ATP, ADP and AMP point to the concept of the 'energy 
, , , „ „ ATP + г ADP) . , , , . . . , . . _ , 
charge (EC = - . ,=;—тт-чг. .»жгч^  a s introduced by Atkinson et al. " I hey 0
 AIP + ADP + AMP ' 
suggested that the regeneration and expenditure of ATP was controlled by the balance 
among the concentrations of the adenine nucleotides ATP, ADP and AMP. Atkinson 
drew a parallel between the adenylate system and an electrochemical storage cell in its 
ability to accept, store, and supply energy. The adenylate energy storage system may 
be described as the sum of the reactions: 
1. ATP + AMP ^ 2 ADP 
2. 2 ADP + 2V^ 2 ATP ^ Η , Ο 
AMP + 2P, ^  ATP +"2H 2 0 " 
The energy charge varies from 0 (only AMP present) to 1 (only ATP present). 
Ad 2 and 3. 
These possible functions are more complicated because both refer to the oxydative 
ATP regenerating system, i.e., the PNC is then supposed to work under aerobic 
circumstances; otherwise the increase in citric acid cycle intermediates would have no 
effect. Aragon et al.41 indeed noticed a fourfold increase of fumarate during the first 
10 minutes of rat skeletal muscle exercise. Although the replenishment of citric acid 
cycle intermediates may also occur via other reactions, e.g. catalyzed by alanine-
glutamate aminotransferase, glutamate dehydrogenase, pyruvate carboxylase and 
malic enzyme, with the aid of an adenylosuccinate synthetase inhibitor the authors 
obtained strong evidence that part, if not all, of the increase in citric acid cycle 
intermediates observed during exercise was due to the generation of fumarate by 
means of the purine nucleotide cycle. 
In this case, however, the turnover of the PNC will also result in a resynthesis of AMP 
and thus counteract the initial shift in the adenylate kinase reaction towards ATP 
production; but because of the low level of adenylosuccinase activity in skeletal 
muscle as compared to the MAD activity, it seems doubtful that AMP regeneration 
could keep pace with AMP deamination during intense mucular work.42 Besides, the 
key regulatory enzyme controlling the resynthesis of adenylates, adenylosuccinate 
synthetase, is inhibited by AMP and ADP and, therefore, not likely to be very active 
during intense muscle stimulation.41 Some studies42 b4 suggest both limbs of the PNC 
operate simultaneously during muscle stimulation, while others44 suggest the two 
limbs operate in series i.e. AMP > IMP during muscle contraction and IMP > 
S-AMP » AMP during the relaxation period following muscle contraction. Any­
how, there is no quibbling about the deamination of AMP to IMP during exercise, 
which is most apparent during anoxic stimulation due to metabolic changes favoura­
ble for activation.45 4~ 
Ad 4 and 5. 
Both proposed functions suggest an involvement of the PNC in the enhancement of 
glyco(geno)lysis during muscular activity. This would mean that in case of MAD-
deficiency, and thus a disrupted PNC, glyco(geno)lysis would take place to a smaller 
extent than in normals. 
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1.4. Some characteristics of AMP deaminase 
The activity of AMP deaminase, a predominantly extramitochondrial enzyme, is 
very high in skeletal muscle in comparison with that of all other tissues, including 
heart and smooth muscles.19 The highest activities are found in white muscle.""1 ^ 
There are several isoenzymes of AMP deaminase, at least three isoenzymes have been 
identified on the basis of quite distinct kinetic and immunologic properties.10 52 
Isoenzyme A is found only in skeletal muscle and diaphragm, isoenzyme В is the 
predominant form in liver, kidney and testes, isoenzyme С is the only form in the 
heart, and hybrids of isoenzymes В and С are found in brain, lung and spleen.''1 
It is beyond the scope of this study to go into the subject of possible different types of 
AMP deaminase in red and white muscle, as put forward by Ogasawara et al.48 and 
Raggi et al.49 In case of the deficiency state the enzyme was almost completely absent 
in all fibre-types.9·1021 
The patients lacking the muscle isoenzyme had nevertheless normal levels of AMP 
deaminase activity in their erythrocytes, suggestive of a hereditary deficiency. 
Crossmixing studies of normal and MAD-defiuent muscle homogenates showed no 
evidence of an enzyme inhibitor, albeit a serum/plasma inhibitor of MAD does exist 
and might traverse the muscle membrane.12,29 ч Rabbit antiscra to human MAD failed 
to react with the AMPD of purified human erythrocytes and other tissues.55 The 
deficit is not an artifactual result of freezing damage since fresh and frozen biopsies in 
the same patient showed equivalent deficits (own experiments and Hshbein's12). 
All these data indicate a specific deficiency of MAD. 
1.5. The consequences of MAD-deficiency. 
The preceding statement find a logical continuation in the question: is there a 
relation between the complaints of exertional myalgia and a disturbance of the purine 
metabolism as a consequence of deficient MAD-activity? 
In attempts to answer this question two approaches may be useful: 1. the analysis of 
changes of purine nucleosides and bases in the venous effluent of the working muscle 
and 2. the analysis of changes of purine nucleotides, nucleosides and bases in the 
exercised muscle itself. 
Bunan1 0 recognized already in 1905 an increase in the 'nonunc acid purine' excretion 
in urine during muscular exercise and in the period immediately following. Although 
the origin of these purines remained obscure to him, he attributed the endogenous 
production of uric acid and other purines in man to muscular activity. The magnitude 
of the increase in the purine excretion depended on the performance delivered. 
Cathcart et al.76 in 1907 and Saiki et al.77 in 1932 confirmed these findings.78 
Because of the relatively recent recognition of MAD-deficiency as the cause of a 
metabolic myopathy, literature with regard to the efflux of purine nucleosides and 
bases under this condition is limited. In 198 3 Patterson et al.,79 and m 1984 Joosten et 
al.15 reported on subnormal amounts of hypoxanthine produced during forearm 
exercise m M AD-dcficiency. The measurement of plasma purines as a marker for ATP 
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degradation in human muscle diseases appeared to be a promising method. Soon after 
these first reports others recognized its value to gain insight in diseases as myo-
phosphorylase- and carnitincpalmitoyltransferase deficiency.s"'so 
The second approach, i.e. the assay of the metabolites in muscle itself, found its 
principal investigators in Sabina et al.4'44 They reported that the skeletal muscle of 
MAD-deficient patients has a lower capacity for energy production than does the 
muscle from non-MAD-deficient patients and controls. From their findings they 
suggested that the PNC has a previously unrecognized function in providing a 
mechanism for preserving the purine nucleotide content of exercising muscle through 
accumulation of IMP, a non-diffusible nucleotide, which can be used to rapidly 
restore the ATP pool during periods of rest.444 
1.6. Screening in MAD-deficiency. 
The major source of ammonia in working muscle is the ammonia liberated 
during the conversion of adenosine monophosphate to inosme monophosphate by the 
en7yme MAD (Fig. I ) . ' 9 Based on this, Fishbein et al.1 used the lactatc/ammonia ratio 
in a forearm test to screen for MAD-deficiency. In their first study on this disease, they 
inflated the sphygmomanometer cuff around the upper arm halfway diastolic- and 
systolic blood pressure as to reach ischaemia and gave their patients a sponge to 
squeeze. This procedure impairs intermdividual comparisons concerning the amount 
of work delivered. Others4 instructed the patient to rapidly open and close his fist until 
muscle fatigue set in or asked the subject to contract maximally for 1 minute.5" So with 
these divergences in screening methods it seems appropriate to ask: which type of 
exercise should be imposed in order to maximally stimulate MAD-activity and to 
adapt this test to a sensitive and specific tool in screening for MAD-deficiency. A 
prerequisite to answer this question is standardization. Munsat''6 developed a stan­
dardized ischacmic test for screening defects in the glyco(geno)lytic pathway using a 
handgrip dynamometer. However, no attempt was made to find out which force level 
and frequency of contractions resulted in blood concentrations of lactate that op­
timally discriminated between patients and controls. Mutatis mutandis the same 
holds true for the ammonia produced. As mentioned before, there seems to be a 
relation between work rate and ammonia production: the higher the frequency of 
muscle stimulation, or the higher the muscle force exerted during contraction, the 
more pronounced the formation of ammonia." " 6 6 6 Н Besides, fast twitch white 
muscle produces more ammonia than red muscle.1 4 , 6 6 4·6 ' ' 
Interlude 2. 
Skeletal muscles are composed of different types of fibres, which can be conven­
iently classified into three categories on the basis of three criteria:™59 
1. the contraction time of the fibre: slow twitch or fast twitch, 
2. the glycolytic capacity, 
3. the oxidative capacity. 
23 
Using a histochemtcal approach to the classification of fibre types and in accordance 
with the findings of Peter,'''' Dubowitz and Brooke1'" the three fibre types are: 
Type I : slow-twitch oxidative, formerly designated as slow-twitch red. 'I hese 
fibres rely predominantly on the aerobic metabolism for the production 
ofA'IP. 
Type Π A : fast-twitch oxidative-glycolytic, formerly designated as fast-twitch 
red. 
Type II В : fast-twitch glycolytic, formerly designated as fast-twitch white. These 
fibres rely mainly on the anaerobic metabolism for the production of 
ATP. 
7 he nerves innervating muscle fibres have their origin in the cell bodies lying in 
the anterior horn of the spinal cord. The neuron which originates in a single anterior 
horn cell will branch to supply many muscle fibres, hunctionally, the anterior horn 
cell, its axon and the muscle fibres supplied by it, behave as one unit, the motor unit.''" 
Burke et д/.6' have shown m cats by direct stimulation of the anterior horn cells the 
presence of three kinds of motor units, corresponding with the type I, type 11 A and 
type Η В muscle fibres and designated as slow-twitch, fast-twitch fatigue resistant, 
and fast-twitch easily fatigued respectively.''" Resistance to fatigue was closely related 
to the activities of the oxidative enzymes.''2 A similar classification of human skeletal 
muscle motor units has been made." 
A requisite for MAD-activity is, of course, a certain amount of substrate, i.e. 
AMP. '1 he formation of AMP implies an imbalance between ATP utilization and ΑΊ Ρ 
rcsynthesis, as is the case in ischaemic exercise. When oxygen and fuel supply can keep 
pace with the demand as in the steady state situation of aerobic metabolism, oxidative 
rephosphorylation of ADP will occur, thereby preventing a dismutation to AMP and 
ATP. 
When one takes into account that the highest activities of MAD are found in type 
II fibres, it is not amazing to find in exercising humans an exponential rise in blood 
ammonia with increasing work loads.64 "' This is in accordance with the assumption 
of an ordered recruitment pattern of muscle fibre types: at low work loads predomi­
nantly slow-twitch fibres will be used, and ammonia production will become more 
evident at higher loads when more fast-twitch fibres are recruited. І м ч - ^ Despite 
these plausible considerations, which suggest a consistent relation between work 
intensity and ammonia production, the increase in ammonia is known to vary widely 
among individuals, even at the same relative workload.''6 № 
This variability in ammonia production may be related, among others, to the wide 
variability in fibre type composition among individuals, and therefore made it worth­
while, in connection with the refinement of the screening method, to perform experi­
ments with different work intensities in order to find the highest ammonia values. 
An important component of the energy at high work loads is derived from anaerobic 
glycolysis, which implies, among others, an accumulation of lactate. Although Fish-
bein12 found a linear relationship between the ammonia and lactate produced in a 
more or less ischaemic exercise test, this linearity in itself is not important for 
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screening purposes. Measuring the lactate concentration offers the possibility to 
estimate the amount of work performed under anaerobic conditions. 
Improvement of screening in exertional myalgia implies muscle contractions in 
such a manner as to produce high levels of lactate and ammonia. In order to achieve 
these requirements it seems logical to impose ischaemia and a high work load. 
Standardization of the contraction force and frequency is obligatory. 
1.7 Genetics 
The mode of inheritance of MAD-deficiency has not been definitely established. 
X-lmked recessive"1 as well as autosomal dominant inheritance19 have been suggested, 
but most authors, including Fishbein12 and M L Kusick,"2 consider it to be autosomal 
recessive. As mentioned before in the review of the study of Hayes et al." the 
possibility of heterozygotes for MAD-deficiency also being symptomatic has not been 
carefully evaluated and is mostly founded on circumstantial evidence. Only in one 
study we found a carrier evaluation.21 It is quite difficult to identify heterozygotes as 
outlined by Fishbein et al.21 because of: 
1. the variation of muscle enzymes with fibre type (e.g., the highest MAD-activity is 
found m type II В fibres); 
2. the non-specific decrease of enzyme activity with disuse, disease or specimen 
mishandling; 
3. the inadvertent inclusion of carriers in the control population. 
Fishbein et al.21 measured MAD levels in six putative heterozygotes, both male and 
female, four of whom complained of exertional myalgia, and found in all six muscle 
specimens MAD-activity of less than 40% of the normal mean value after correction 
for their fibre-type distribution. Hence they concluded that the heterozygous state 
does exist and that the inheritance pattern is autosomal recessive. 
1.8 The intents. 
In the preceding paragraphs of this chapter the questions and controversies 
which exist with regard to myoadenylate deaminase deficiency have been outlined. As 
such these issues are the subject of this study. 
In each of the following 6 chapters an answer is formulated to a specific question that 
has arisen. Previous to the enumeration of the questions it seems wise to give a 
synopsis of the problems encountered. A prerequisite to study a newly described 
disorder is the delineation of this disturbance m order to distinguish it from other 
pathologic entities. Only then is it possible to perceive a specific underlying pa­
thophysiological mechanism, if any. 
So the first implication is the necessity of developing a reliable screening method, 
certainly when a discriminative set of symptoms and/or signs is not on hand. Once the 
deficiency is easily diagnosed by means of a screening test, the next step is to look for a 
relationship between the complaints, i.e. exertional myalgia, and a disturbance in 
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purine metabolism as a consequence of the deficiency and as the biochemical base of 
the pathophysiology. At last, if a disease is supposed to be inherited, one wonders 
about its mode of inheritance and frequency of occurrence. 
So the aims of this thesis concerning the deficiency of myoadenylate deaminase were 
to find answers to the following questions: 
1. The development of a non-invasive screening method in order to minimize the 
number of muscle biopsies needed. 
2. Does standardization improve the specificity and sensitivity of the screening test? 
3. What are the biochemical consequences of MAD-deficiency concerning purine 
metabolism as measured in the venous effluent of exercising muscle? 
4. What are the biochemical consequences of MAD-deficiency concerning purine 
metabolism as measured in muscle itself? 
5. What arc the genetics of the deficiency on base of the screening of families of 
probands? Do eventually newly diagnosed patients in these families have com-
plaints? 
6. What is the frequency of occurrence of MAD-deficiency in muscle biopsies of 
patients without exertional myalgia (retrospective) and in patients with exertional 
myalgia which are screened with the standardized ischaemic exercise test (prospec-
tive)? These frequencies are important for the clinical relevance of the deficiency. 
All the patients in this study arc listed in the Appendix. 
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SUMMARY 
Subjects with myopathies associated with certain еплуте defects often show 
abnormal concentrations of lactate (LA) and ammonia (NH,) in blood after ischemic 
exercise. Myoadenylate deaminase (MAD) deficient patients produce only small 
amounts of NH,, whereas LA rises to normal levels. On the other hand, patients with 
certain enzyme deficiencies in the glyco(geno)lytic pathway show the opposite. 
However, the concentrations in blood are dependent on the exercise performed. 
Standardization of tests for screening purposes, therefore, is necessary. For ischemic 
contractions, experiments were performed to find the optimal combination for force 
and frequency, using the highest LA and NH, concentrations in blood as criteria. 
Eleven healthy subjects performed ischemic isometric contractions with a handgrip 
dynamometer at frequencies of 30 and 50/min— ' and force levels of 50%, 65%, and 
80% of maximal voluntary contraction force (MVC). A combination of 30/min—' 
and 80% MVC was found to give the best results. 
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INTRODUCTION 
In 1978, Fishbein et al.4 discovered a new muscle disease associated with weak-
ness and cramping after exercise myoadenylate deaminase (MAD)deficiency. MAD 
catalyzes the irreversible deamination of adenosine monophosphate (AMP) to inosine 
monophosphate (IMP). Rcsynthesis of AMP occurs by the sequential action of 
adenylosuccinate synthetase and adenylosuccinase. The reaction chain thus con-
stituted is called the purine nucleotide cycle (Fig 1). Necessary for the purine nu-
NH, 
t _^ 
AMP / > - IMP V urate 
^ ^ rnvoadenylatcdeaminase 
adenylosuccinate 
ligure 1 Main characteristics of the purine nucleotide cvcle Modified after Sahlin et al " See text for 
explanation 
cleotide cycle are aspartate and guanosinc triphosphate (GTP), while fumarate, 
guanosine diphosphate (GDP), organic phosphate, and ammonia (NH,) are formed. 
The purine nucleotide cycle is known to be active during exercise and especially 
during ischemic exercise 8 " '5 '* Based on this fact, Fishbein et al.1 devised a simple 
screening test for subjects suspected of MAD-deficiency. The subjects were asked to 
squeeze a sponge for 1 or 2 minutes. Lactate (LA), as an indicator for glycolytic 
activity, and NH, as an indicator for MAD-activity, were measured in blood, which 
was sampled after the exercise period. In 'normal' subjects, a positive correlation was 
found between the LA and NH, produced. Subjects with MAD-deficiency showed 
very little NH, production relative to the production of lactate. 
The relationship between NH, and LA produced during exercise not only reveals 
information about a defect in the purine nucleotide cycle, but several enzyme deficien-
cies in glyco(geno)lysis can also be detected. Among these are the Phosphorylase, 
phosphofructokinase, phosphoglycerate mutase, phosphoglycerate kinase, and lac-
tate dehydrogenase deficiencies (see DiMauro et al.' for references). Almost no LA 
can be formed, whereas NH, formation is not inhibited because the purine nucleotide 
cycle is not affected 
It can be deduced that the defects described will appear clearest during heavy 
anaerobic muscle contractions. I hese exercise tests for screening patients vary from 
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one clinic to another and are not strictly standardized. Fishbein et al.,4 in their first 
paper on this disease, gave their patients a sponge to squeeze. Sabina et al.I2 instructed 
the patient to rapidly open and close the fist until muscle fatigue sets in, whereas 
Hayes et al.5 asked the subjects to squeeze an inflated sphygmomanometer cuff for 2 
minutes. Brooke et al.' asked their subjects to contract maximally during 1 minute. 
Munsat10 developed a standardized ischemic test for screening defects in the 
glyco(geno)lytic pathway using a handgrip dynamometer. A fixed frequency of 60 
contractions per minute was imposed, and the workload was varied by attaching 
different sprmgloads. However, no attempt was made to find out which force level 
and frequency of contractions resulted in blood concentrations of LA that optimally 
discriminated between patients and controls. 
The purpose of this study is to develop a standardized handgrip test with an 
optimal combination of force and frequency to screen for MAD-deficiency as well as 
for several glyco(gcno)lytic enzyme deficiencies. Criterion for the optimal combina­
tion are the highest concentrations of LA and NH, after exercise. Ischemic exercise 
was chosen because the LA10 and NH, concentrations reach higher levels than they do 
m nonischemic exercise. 
MATERIALS AND METHODS 
Subjects. Eleven healthy subjects without neuromuscular symptoms participated 
in the study. There were 4 females, with a mean age of 26(22- 31 ) years, a mean weight 
of 60(57-65)kg, and mean height 167(159-172)cm, and 7 males, mean age 38(24-
54)years, mean weight 78(69-93)kg, and mean height 184(177-198)cm. The subjects 
performed isometric handgrip tests with the dominant hand at contraction frequen­
cies of 30 and 50/min—' and force levels of 50%, 65%, and 80% of the maximal 
voluntary contraction force (MVC). The tests were interspaced by at least 1 week. The 
force and frequency levels were obtained from a preliminary study in which it was 
shown that a test duration of 1-3 minutes was a prerequisite to be sure that the 
anaerobic pathway is heavily taxed, and frequencies over 50/min —' were too high to 
execute the test correctly. 
Procedure. The subject was seated on a chair, with the forearm horizontally on 
the level of the handgrip dynamometer (Fig. 2). '1 he handgrip width was adjusted to 
the size of the hand: the medial phalanx of the middle finger had to be perpendicular 
to the proximal phalanx. Next, the MVC was determined. The highest value of three 
maximal contractions, interspaced by 1 minute, which could be maintained for at 
least 3 seconds, was taken as the MVC. After a rest of 10 minutes, a I eflon catheter 
(Abbocath 18G. о 0.9 mm, Abboth Ireland Ltd, Sligo, Republic of Ireland) was 
inserted in an antecubital vein, and 3 minutes later, 10 ml of blood was sampled to 
obtain the resting values of LA and NH,. Two minutes later, a cuff around the upper 
arm was inflated to 200 mm Hg, and the subject was asked to start exercising at a 
predetermined frequency and force level. Each subject performed seven tests, includ­
ing a preliminary test. The following order of the different combinations of force and 
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Figure 2. The experimental setup: handgrip dynamometer, recorder, metronome. 
frequency levels was randomly assessed per subject. At the moment the subject could 
no longer deliver any force, despite encouragements from the leader of the experi­
ment, the test was stopped. Immediately after deflation of the cuff, a blood sample 
was taken, and this was repeated after 3, 5, and 7 minutes. The highest levels for LA 
and NH, after exercise in all 77 experiments were reached for LA 29 times imme­
diately after exercise, 45 times at 3 minutes, and 3 times at 5 minutes. For NH,, the 
data are 19 times immediately after, 32 times at 3 minutes, 23 times at 5 minutes, and 
3 times at 7 minutes. LA and NH, peaked 47 times at the same moment. In the other 
cases, the time difference in the appearance of the peak was generally not more than 3 
minutes. In general, the subjects who showed the highest value earlier or later did this 
after all experiments, but not exactly at the same time. 
Physiologic Variables and Apparatus. The force was measured with a strain-
gauge dynamometer. The amplified signal was continuously recorded on a strip chart 
recorder and was presented to the subject. The required force level was indicated on 
the recorder with a solid line. Frequency was indicated by a metronome at frequencies 
of 30 or 50 contractions per minute. To obtain an indication for the amount of muscle 
work delivered, the total impulse (TI), that is, the sum of the integral of force and time 
(in kgf χ sec) of all contractions, was measured with a Kipp BC-1 integrator (Kipp, 
Delft, The Netherlands). The number of contractions and the time until exhaustion 
were derived from the registration of the stripchart. Blood was analyzed for NH, on a 
Multistatt III centrifugal analyzer (Instrumentation Laboratory, Harrow, Middlesex, 
UK), with an adaptation on the enzymatic UV-test, as described by Da Fonseca-
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Wollheim and Maigatter.2 LA was determined enzymatically, with minor modifica­
tions, after Henry et al.6 
When appropriate, statistical comparisons between the blood concentrations 
after exercise were made by three-way analysis of variance (ANOVA-force level 
effects, frequency effects, and intermdividual differences). A Ρ < 0.05 level of signifi­
cance was used for these comparisons. 
RESULTS 
MVC in the first experiment was significantly lower than the MVC in repetitions. 
The mean MVC for all subjects during the six successive experimental days were 
100%, 110%, 114%, 112%, 112%, and 112%, respectively. 
The individual LA and NH, concentrations measured at rest in all six test 
situations ranged from 808 ± 49 to 1272 ± 102 μπιοΐε.liter-1 (mean ± SE) and 22.5 
± 2.8 to 47.2 ± 2.2 цтоіе.іііег— ',respectively. The highest concentrations measured 
after the exercise period are presented in Table 1 for each combination of frequency 
and force level. 
Analysis of variance revealed that no significant differences existed between the 
frequencies for maximum lactate and ammonia. However, a significant difference 
was found between the force levels for LA (P < 0.05). The highest force level showed 
the highest lactate concentration. For NHj, no such difference could be found. The 
same applied when the delta value (maximal concentration - concentration at rest) 
for LA (Δ LA) and NH, (Δ NH,) were taken into account. 
In Table 1 is also presented the time to exhaustion for each combination of force 
and frequency. Frequency and force level were the main determinants of the number 
of contractions and the time to exhaustion. ANOVA indicated that TI was dependent 
on the frequency (P< 0.001), TI being higher at 30.mm- 1 than at 50.mm ' (Table 1). 
No differences for TI between the forte levels could be found (P > 0.05). 
Table 1 Maximum ammonia (NH,) and lactate (I A) concentrations m blood (ßmol I '), total impulse ( 11, 
kgf x sec), and time to exhaustion (FT, seconds) for each combination of force (% MVC) and frequency 
(per minute) during ischemic isometric handgrip contractions m normal subjects (n = 13, mean ± 41 M) 
Frequency 
30 
NH, 
IA 
TI 
ET 
50 
NH, 
LA 
TI 
ET 
50 
169 ± 15 
5365 ± 491 
1661 ± 155 
159 ± 6 
159 ± 17 
S502 ± 401 
1320 ± 89 
116 ± 4 
Percent M V C 
65 
169 + 19 
5640 ± 491 
1696 ± 104 
112 ±5 
162 ± 18 
5395 ± S45 
1303 ± 85 
86 ± 3 
80 
174 ± 17 
60И ± 594 
16S2 ± 135 
89 ± 4 
166 ± 17 
6605 ± 449 
1309 ± 108 
68 ± 3 
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DISCUSSION 
In the first testing of the subject, the MVC was significantly lower than in the 
remaining tests. Kroll7 described the same phenomenon: 3 weeks after the first 
determination of the MVC, the MVC appeared to be 8-15% higher. The most 
plausible explanation is a motor learning effect, as it is very unlikely that any 
physiologic variable is altered. The lower MVC in the first visit has not influenced the 
results, because the following order of the experiments per individual was ran-
domized prior to the experiment. In practice, however, it may be worthwhile to 
perform the MVC test twice, interspaced by a resting pause of several minutes at the 
first session, to avoid underestimation of the MVC. Time to exhaustion appears to be 
almost completely determined by the force level and frequency of repetition. Interin-
dividual differences, however, still accounted for a significant part of the variance. 
The MVC was not related to the time to exhaustion, which confirms the findings in 
continuous isometric exercise.14 
As patients with an enzyme deficiency in the glyco(geno)lytic pathway or in the 
purine nucleotide cycle are known to make lesser amounts of LA and NHj during 
muscle work, it is essential for screening purposes that the control subjects investig-
ated do have the highest possible concentrations of LA and NH,. The highest LA 
concentrations in blood are found when a force level of 80% MVC was imposed 
(Table 1). Furthermore, there is a tendency for the NH, levels to be highest also at 
80% MVC (Table 1). The findings for the LA levels are consistent with data from 
Wahren,17 who used intermittent isometric exercise with a handgrip dynamometer. 
The highest concentration of lactate was found with the highest force imposed. For 
the purpose of a screening test, these data indicate that the force level to be chosen 
should be 80% MVC. 
It is not easy to determine the optimal frequency at which to perform the test. 
There was a tendency for the maximal NH, concentrations to be higher at the 
frequency of 30 contractions per minute as compared with the frequency of 50 
contractions per minute (Table 1). Moreover, some subjects had difficulties in main-
taining the frequency of 50 contractions per minute, whereas the frequency of 30 
contractions per minute could be fulfilled without difficulties. Therefore, the frequen-
cy of 30 contractions per minute seems to be most appropriate for a standardized 
procedure. 
It is difficult to explain why NHj was not significantly higher when the muscle 
'work' was at its hardest. As comparative literature data for these sorts of tests are not 
available, it can only be speculated that the production of NH, is already maximal at 
the lowest exercise level used here. Another explanation might be that NH, is slowly 
released from the muscular tissue (for references see Mutch and Bannister' '), showing 
a peak level after exercise that is not representative for the production in the muscle. 
The data for TI did not add any extra information to that obtained from the 
relation between performance and LA or NH, (see Table 1 ). This was probably due to 
the relatively small range of force levels used and the large inter- and intraindividual 
differences. Measurement of TI in a screening test using the force levels and frequen-
cies used here does not seem to be necessary, at least in a group of healthy subjects, 
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such as those used here. The future might show that a small TI is an indication that the 
subject probably suffers from a defect in the glyco(geno)lytic pathway. 
For the chosen combination of force level and frequency (respectively, 80% 
MVC and 30 contractions per minute), the relationship between the highest Δ NH, 
and Δ LA is given in Fig. 3. In this figure, data of LA and NH, are included from six 
McArdle patients9 and eight MAD-deficient patients4 observed in the Department of 
Neurology. The patients performed the exercise test with the same combination of 
force (80% MVC) and frequency (30/min—') as the controls. It should be noted that 
their resting values of LA and NH} are not essentially different from those of the 
control subjects. These data suggest that this standardized test might be valuable in 
screening subjects with enzyme deficiencies in the glyco(geno)lytic pathway. 
In summary, for screening subjects suspected of either an enzyme deficiency in 
the glyco(geno)lytic pathway or a MAD-deficiency, an ischemic isometric handgrip 
test is proposed with a contraction frequency of 30.min—' and a force level of 80% 
MVC. A preliminary reference figure is given for the relationship between LA and 
NHj. 
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Figure 3. The highest increase (A), compared with rest, of LA and NH, after ischemic isometric handgrip 
exercise with 80% MVC and 30 contractions per minute (11 control subjects, · ; MAD-deficient patients, 
+; McArdle patients, x). Regression lines for controls: Δ NH, = 0.027 Δ LA + 1; Δ LA = 26.64 Δ NH, + 
1525; r = 0.83. 
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SUMMARY 
An ischemic forearm test with simultaneous measurement of both lactate and 
ammonia can be used as a screening method for myoadenylate deaminase (MAD) 
deficiency and for various glyco(geno)lytic defects. A standardized and a nonstandar-
dized test have been compared in a group of 186 patients with exertional myalgia. 
Standardization of the ischemic forearm test has led to greater yields of both lactate 
and ammonia in venous return blood of patients and controls. The sensitivity of the 
proposed test procedure in detecting MAD-deficient patients was 100%, whereas the 
specificity amounted to 98.8% among exertional myalgia patients. 
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INTRODUCTION 
With the development of a staining procedure for myoadenylate deaminase 
(MAD) in muscle biopsies, it became clear that the deficiency state for this enzyme 
was not rare at all.5 Estimations of its occurrence ranged from 1% —2% in leftover 
biopsy material5'7'16 to 8.3% in exertional myalgia patients/ making it the most 
common of all known enzyme deficiencies of skeletal muscle.4 
The clinical symptoms of this metabolic myopathy are ill-defined and encompass 
exercise-induced muscle pain and soreness, fatigue, and cramps. This set of com-
plaints, however, can have a variety of causes, including several metabolic disorders. 
The high prevalence, in combination with the nonspecific clinical symptoms of MAD-
deficiency, illustrate the need for a reliable screening test. However, several reports in 
the literature have described pitfalls in the ischemic forearm test.1·8 
Ammonia is liberated during the conversion of adenosine monophosphate 
(AMP) to inosine monophosphate (IMP) by the enzyme MAD. This reaction is the 
major source of ammonia in working muscle.9 Based on this, Fishbein et al.3 used the 
lactate/ammonia ratio in a forearm test to screen for myoadenylate deaminase defi-
ciency. Patients with MAD-deficiency have a high lactate/ammonia ratio in this test, 
whereas patients with glyco(geno)lytic defects (e.g., McArdle's disease) invariably 
have a low ratio. A major problem in the interpretation of this screening test often lies 
in the low amount of lactate and ammonia produced by the patient during exercise. 
Standardization of the contraction force and frequency17 could be an answer to this 
problem. 
This article compares the nonstandardized ischemic forearm test with a stan-
dardized version of the test in screening patients with exertional myalgia. Biochemical 
data are presented on several neurologic patient groups. Various ways of expressing 
the biochemical data have been studied in order to find the best method to discrimi-
nate between MAD-deficient patients and others. 
MATERIALS AND METHODS 
Subjects. Four groups of patients were subjected to an ischemic forearm test 
(Table 1). The patient groups la and 4a did the nonstandardized exercise test, and the 
patients in the groups lb , 2, 3, and 4b did the standardized exercise test. The patients 
in group 1 had visited the outpatient ward of the hospital during 2 years of study with 
exercise-related muscular complaints or with muscle pain, soreness, fatigue, or 
cramps. Neither MAD-deficient nor McArdle patients have been included in group 1. 
The MAD-deficient group contained six patients in whom the defect was first 
discovered in a muscle biopsy. Three patients resulted from a systematic search with 
the exercise test among exertional myalgia patients. The diagnosis in all cases in this 
latter group was confirmed enzymatically, as well as histochemically, in a muscle 
biopsy. McArdle's disease was confirmed by the absence of both Phosphorylase 
protein and Phosphorylase enzymatic activity in all patients. The control group 
consisted of healthy volunteers (students and hospital personnel). All patiens and 
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Table 1 Description of patient group;. 
Group 1 bxertional mvalgia group 
(la) Nonstandardued test η = 116, 71 men, 45 women, mean age 28 years, range 4-71 years 
(lb) Standardized test η = 70, 33 men, 37 women, mean age 34 )ears, range 12-58 years 
Group 2 MAD-dcficient group η = 9, 9 men, mean age 4Ü years, range 14-66 years 
Group 3 McArdle group η = 5, 1 men, 4 women, mean age 20 years, range 8-27 years 
Group 4 Control group 
(4a) Nonstandardi7ed test η = 32, 15 men, 17 women, mean age 28 years, range 21-48 years 
(4b) Standardized test η - 22, 13 men, 9 women, mean age 32 years, range 21-55 years 
controls gave their informed consent. 
Groups lb an 2 may be considered to be a representative sample of patients for 
whom the standardized ischemic forearm test is clinically indicated. 
Ischemic Forearm Test. Preliminary experiments indicated higher lactate and 
ammonia production in cases of ischemic exercise as compared to nonischemic 
exercise. Ischemic exercise has been used in this investigation. 
7 he nonstandardtzed test. Blood samples for the determination of ammonia and 
lactate were drawn from the antecubital vein before exercise and at 0, 2, and 4 
minutes after exercise (Fig. 1). During exercise, a sphygmomanometer cuff, inflated 
well above the systolic blood pressure, was around the dominant upper arm of the 
subject. The cuff was deflated immediately after the exercise period. All subjects 
performing the test were asked to open and close the fist of their dominant arm 
vigorously for 2 minutes. 
The standardized test. Isometric handgrip contractions till exhaustion at 80% 
maximal voluntary contraction force and a rate of 30/min were used, as described 
previously.1' Blood samples were drawn from the antecubital vein before the exercise 
and at 0, 3, 5, and 7 minutes thereafter (Fig. 1). Analytical techniques for the 
measurement of lactate and ammonia have been described elsewhere.17 
Classification as MAD-deficient or Non-MAD-dcficicnt. Using discriminant 
analysis, a criterion has been developed for classifying exertional myalgia patients as 
MAD-deficient or non-MAD-deficient. Three discrimination lines, calculated accord­
ing to Rao,1 ' are presented in Fig. 2. The distribution of the ammonia production in 
both groups is the first of three factors that arc important for the calculation of the 
discrimination lines. The second factor that should be considered is the prevalence or 
prior probability of belonging to either one of the groups. In our patient group, the 
prevalence was 4.1% (3 MAD-deficient patients among 73 patients with exertional 
myalgia). For this reason, all calculations were carried out using prior probabilities 
around this value (i.e., 1%, 4.1%, and 8.2%). As this study may not be regarded as an 
accurate prevalence study, a wide prevalency range has been taken into account. The 
third factor is the so-called 'loss,' in case a patient is misclassified. If a MAD-deficient 
patient is classified as non-MAD-deficient, the loss exists as the time wasted to find 
another diagnosis. If a control is classified as a MAD-deficient patient, the loss exists 
as an unnecessary biopsy. The loss in case of a misclassified control is arbitrarily set at 
1. In case we assume the misclassification of a non-MAD-deficient patient equally 
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50 . 
0 2 
h*· Postext reise 
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Time in minutes 
tigure 1 Mean lactate and ammonia production (1 2 SEM) m patients (controls plus exertional myalgia 
group) for the standardized (9) and the non standardized (ir) forearm test 
(A) Ammonta, (B) Lactate 
serious as the misclassification of a MAD-deficient patient, the loss, I. = 1, applies. 
The loss in case of missing a MAD-deficicncy, however, is more serious than the loss 
in case of a false-positive result, bor this reason, loss values of 1 = 1 0 and L = 100 
have been used Still higher values for L are not considered, because the number of 
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false-positive controls has to remain acceptable. The choice of L will be discussed 
below. Unfortunately, there is no simple alternative method for discriminating be­
tween MAD-deficient and non-MAD-deficient patients. The only possibility, and at 
the same time the gold standard, is the muscle biopsy. As indicated in Fig. 2, we did a 
muscle biopsy on 46 of the 106 patients and controls included in our study (43%). 
Data on the sensitivity and the specificity of the test will be presented. 
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RESULTS 
Standardization of the Screening Test. Figure 1 shows the results of the ischemic 
forearm test carried out by patients with exertional myalgia and by controls (groups 1 
and 4). The standardization procedure gave considerably higher blood levels for 
lactate and ammonia (P < 0.05). For this reason, only the results obtained with this 
standardization procedure are presented below. 
Physiologic Data. The total impulse (in kg.min) expended by controls, exertional 
myalgia patients, and MAD-deficient patients without an associated neuromuscular 
disorder was, respectively, 31.5 (± 4.8), 30.1 (± 8.8), and 30.3 (± 7.6), whereas their 
endurance time in seconds was, respectively, 87.5 (± 8.4), 101.8 (± 24.4), and 91.3 
(± 14.3). These figures are related to men older than 15 years. A comparison between 
women was not possible due to the lack of female MAD-deficient patients. Two-way 
analysis of variance revealed no statistically significant differences between the dif-
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ferent groups, although the endurance time tended to be longer in the exertional 
myalgia group in comparison to the control group (P = 0.09). 
Blood Levels for Lactate and Ammonia. Mean pre- and postexercise levels of 
lactate and ammonia are shown in Table 2. Within one group, interindividual 
differences exist in the lactate and ammonia concentrations after exercise. Some 
patients had maximal blood levels at t = 0, immediately after exercise, whereas others 
reached maximal levels later on (Table 3). 
Table 2. Mean lactate and ammonia levels (цтоі/іігег) for the various diagnostic groups performing the 
standardized test. 
Exertional 
(n = 70) 
MAD-defn 
(n - 9) 
McArdle 
(n = 5) 
Control 
(n - 22) 
Kxcrtional 
(n = 70) 
myalgia 
cient 
myalgia 
MAD-dcficicm 
(n = 9) 
McArdle 
(n = 5) 
Control 
(n = 22) 
Pre 
1021 
(297)* 
1001 
(326) 
906 
(203) 
1025 
(260) 
Pre 
42 
(ID 
46 
(8) 
47 
(П) 
38 
(ID 
0 
484') 
(1605) 
4865 
(1082) 
1100 
(228) 
5672 
(1814) 
0 
143 
(74) 
54 
(8) 
399 
(204) 
167 
(58) 
Lactate at time (ι 
3 
4548 
(1233) 
3910 
(892) 
890 
(115) 
5177 
(13Π) 
Ammonia at time 
3 
150 
(56) 
56 
(8) 
200 
(37) 
170 
(47) 
mm) 
5 
3963 
(1214) 
3195 
(1081) 
1052 
(103) 
4712 
(1233) 
(mm) 
5 
142 
(59) 
53 
(6) 
142 
(35) 
175 
(47) 
7 
3339 
(991) 
2849 
(1039) 
1094 
(87) 
4168 
(1084) 
7 
120 
(53) 
51 
(7) 
107 
(37) 
162 
(45) 
Standard deviation in parentheses 
Table 3. The number »f exertional myalgia patients at the time of their respective maximal lactate and 
ammonia levels. 
Time of maximal 
lactate level 
Maximal NH, level at 
t = 0 
24 
6 
0 
0 
t = 
11 
13 
0 
0 
3 t = 
9 
4 
2 
0 
5 t = 7 
0 
1 
0 
0 
44 
24 
2 
0 
t = 0 
t = 3 
t = 5 
t = 7 
30 24 15 70 
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Results of Discriminant Analysis. Three ways of analyzing the ammonia and 
lactate data have been used.(l) Delta value maximal postexercisc value minus the 
preexercise value.(2) Relative values: maximal postexercise value/preexercise val-
ue.(3) Integrated values: integrated value of postcxercise minus preexercise con-
centrations. For statistical reasons, the data were also analyzed after a logarithmic 
transformation. There are two criteria to decide which way of plotting gives the best 
results first, the percentage of misclassifications in both the MAD-deficient and the 
non-MAD-deficient groups (i.e., the sensitivity and the specificity of the test), and 
second, the posterior probabilities. This is the probability of belonging to one of the 
two groups given the outcome of the measurements. The posterior probability with 
respect to correct classification has been calculated for each patient (Fable 4). The 
value for the posterior probability should ideally be close to one. It is not influenced by 
the value of the loss factor L 
Table 4 shows that log (delta) values and log (integrated) values both give good 
results for the posterior probabilities with all prevalency values considered. The 
percentage of misclassifications in the MAD-deficient and the non-MAD-defiuent 
groups (i.e., sensitivity and specificity of the test) appear to be similar for both ways of 
calculating. As will be discussed, it was decided to use the log(delta) values in practice. 
Using log(delta) values and the L = 10 line, the specificity of the test is 98 8% and the 
sensitivity amounts to 100%, as can be deduced from I able 4. Figure 2 shows the 
discrimination lines thus obtained at three L values. In the figure, the log(delta) values 
have been retransformed to delta values. 
Table 4 Mean posterior probabilities and percentage misclassifications 
Previlencc for MADD 
Delta 
I og (delta) 
Relative 
Log (relative) 
Integrated 
I og (integrated) 
Prevalence for MADD 
1 oss factor I 
Delta 
I og (delta) 
Relative 
I og (relative) 
Integrated 
Log (integrated) 
0 01 
Non MADD 
1 0 
1 0 
1 0 
1 0 
10 
1 0 
1 
Non MADD 
0* 
0 
0 
0 
0 
0 
MADD 
0 59 
10 
031 
0 76 
0 60 
1 0 
MADD 
125 
0 
24 0 
12 5 
0 
0 
Mean posterie ir probabil 
0 041 
Non MADD 
1 0 
0 99 
1 0 
10 
10 
0 99 
Percen 
MADD 
0 79 
1 0 
0 62 
0 90 
0 79 
1 0 
ity 
0 082 
Non MADD 
1 0 
0 98 
1 0 
1 0 
10 
0 98 
tage misclassifications 
0 041 
10 
Non-MADD 
0 
12 
0 
1 2 
0 
13 
MADD 
0 
0 
0 
0 
0 
0 
MADD 
0 87 
1 0 
0 76 
0 94 
0 87 
1 0 
100 
Non MADD 
0 
7 1 
0 
1 2 
0 
6 6 
MADD 
0 
0 
0 
0 
0 
0 
* Vilucs in percentages 
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McArdle's Disease. Discrimination between McArdle patients and others turned 
out to be fairly easy in the standardized ischemic forearm test. All McArdle patients 
had a delta ammonia value of > 100 цтоі/іііег in combination with a delta lactate 
value of < 400 μιτιοΙ/ΙιίεΓ (Fig. 2). 
DISCUSSION 
Most authors in the literature have used an ischemic test procedure for forearm 
exercise.1'6,8·1015 Others prefer to work under nonischemic conditions.212 Preliminary 
experiments indicated higher lactate and ammonia production in cases of ischemic 
exercise as compared to nonischemic exercise. For that reason, we developed a 
standardized ischemic forearm test.17 This investigation shows that significantly 
greater amounts of lactate and ammonia are found in the standardized test than under 
nonstandardized conditions (Fig. 1). This holds true in controls and in patients with 
exertional myalgia. 
From Fig. 2 it is evident that in order to discriminate between MAD-deficient 
patients and controls, a certain amount of lactate should be produced. A delta lactate 
value of 4.5 mmol/liter has been mentioned by Fishbein2 in this respect. Taking into 
consideration the findings in Fig. 2, a delta lactate value of 2.5 mmol/liter is sufficient 
in our experience. 1 wenty-one percent of our patients had a lactate production of less 
than 2.5 mmol/liter with the unstandardi7ed test. This percentage diminished to 12% 
under standardized conditions, thereby improving the value of this screening test. The 
test is indecisive in one of eight patients. Sometimes a repetition of the test proved to 
be helpful in these cases. 
The appearance in time of lactate in venous blood samples after ischemic exercise 
is different from that of ammonia. In general, the ammonia level in venous blood 
peaked a little later than lactate. Also, between individual patients there were impor­
tant differences in the time of appearance of maximal concentrations. Furthermore, it 
was observed that in some patients, lactate and ammonia remained relatively high 
during 7 minutes, whereas in others, there was a rapid decline to almost baseline 
values within that period. In clinical practice, it is therefore necessary to sample at 
various times after ischemic exercise. 
A noteworthy finding was the unusually high ammonia production in three of 
our five McArdle patients (Fig. 2). A plausible explanation for this phenomenon has 
been put forward by Rumpf et al.14 The muscular adenosine triphosphate (ATP) 
concentration in patients with McArdle's disease decreases rapidly upon ischemic 
exercise because of the enzymatic block in glyco(geno) lysis. The myokinase reaction 
generating 1 mol ATP and 1 mol AMP from 2 mol adenosine diphosphate (ADP) is 
enhanced by the decreased ATP/ADP ratio. In order to reach a further shift in the 
myokinase reaction in the direction of ATP synthesis, AMP is removed and converted 
into IMP by the enzyme MAD. ATP generated in this way can partially compensate 
for the lack of ATP production in the glycolysis. The increased flux through the 
myokinase reaction is to be considered as a compensation for the existing metabolic 
block. The increased deamination of AMP into IMP gives rise to a higher production 
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of ammonia in a muscle deficient in Phosphorylase than in a normal muscle under the 
same conditions. 
The intermdividual variation in the shape of the ammonia and lactate curves 
could have implications for what turns out to be the most appropriate way of plotting 
lactate and ammonia values in order to obtain an optimal discrimination of MAD-
deficient and non-MAD-deficient patients. For this reason, various ways of plotting 
the data have been used. Until now, delta values have been used by most authors.1'6,12 
Theoretically, it is to be expected that integrated values (i.e., a value approximating 
the total amount of metabolite produced during exercise) would result in a more 
sensitive discrimination of MAD-deficient and non-MAD-deficient patients. Discrim-
inant analysis showed the results of these two ways of plotting (delta and integrated 
values) to be the best and to be equally good, as judged by the percentage of 
misclassifications and the values found for the posterior probabilities (Table 4). In 
consequence, there was no reason to initiate the use of integrated values. For the sake 
of both uniformity and simplicity, we propose to continue the use of (log)delta value 
in the interpretation of the results of the ischemic forearm test. 
Sensitivity and specificity of the screening test depend on the discrimination line 
that is used in clinical practice (Fig. 2). None of our MAD-deficient patients had a 
delta ammonia value that exceeded the line L = 1. To be sure not to miss a deficiency 
in the future, it is proposed to use the line L = 10. This implies that the number of non-
MAD-deficient patients suspected of having the deficiency will increase. Upon muscle 
biopsy, as the ultimate diagnostic procedure, these patients will prove not to be 
deficient for the enzyme. They have been false-positive in the screening test. It is quite 
possible that these false-positive tests refer to patients with the carrier status for the 
enzyme deficiency, which has been recently described by Fishbein et al.4 Forty percent 
of the mean normal enzyme level was found in muscular tissue of MAD-deficient 
carriers, possibly giving rise to a lower ammonia production upon exercise. Type 1 
fiber predominance could be an alternative explanation for relatively low ammonia/ 
lactate ratios in the ischemic forearm test, as type 1 fibers are low in MAD activity.2,4 
Our data on the specificity and sensitivity of the ischemic forearm test are hard to 
compare with other studies in the literature, because the number of patients investig-
ated in other studies is too small to give reliable results in this respect.2,610·12 
Kelemen et al.8 and DiMauro et al.1 are uncertain about the usefulness of the 
forearm test as a screening test for MAD-deficiency. They describe a healthy volunteer 
in whom the ammonia level in venous return blood hardly increased with exercise.1 
We have found similar cases among our patients and controls. In these cases, 
however, we also found a low delta lactate value. This combination of results (low 
delta lactate plus low delta ammonia) means that the test is indecisive. We have 
observed that this can occur m healthy, well-motivated controls as well as in patients 
with exercise-related muscular complaints. In our opinion, muscular biopsy is indi-
cated if repeated standardized ischemic exercise tests remain indecisive, although we 
realize that this does not prove that the patient has muscular pathology. The simul-
taneous measurement of lactate and ammonia thus contributes essentially to the value 
of this screening test. It allows the detection of MAD-deficiency, but moreover, it 
improves the screening for glyco(geno)lytic defects as well. For instance, McArdle 
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patients produce only little lactate but much NHj. By the simultaneous measurement 
of both metabolites, they can be discriminated readily from patients that produce 
small amounts of both lactate and NH, during this test. 
In summary, as shown in this study, the standardized ischemic exercise test with 
simultaneous measurement of lactate and ammonia proved to be an invaluable tool in 
the screening of patients with exercise-related muscular complaints. 
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SUMMARY 
1. Plasma adenosine, mosine and hypoxanthine concentrations were assayed in 
seven control subjects, five myoadenylate deaminase deficient (MADD)patients and 
six McArdle patients before and after ischaemic forearm exercise. 
2. The plasma adenosine increase was very low in all test groups and there were 
no significant differences. 
3. The MADD patients showed a significantly lower increase of plasma inosine 
and hypoxanthine after exercise as compared with the controls. 
4. In the McArdle patients the increase in plasma inosine and hypoxanthine after 
exercise did not differ significantly from the values measured in the controls. 
5. The ischaemic exercise test with measurement of plasma inosine and hypox-
anthine might be of diagnostic value in MAD-deficiency, but not in McArdle's 
disease 
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INTRODUCTION 
Recently the absence of plasma hypoxanthine elevation in response to forearm 
exercise was demonstrated in four myoadenylate deaminase deficient (MADD)-
patients,1 whereas an abnormal increase of hypoxanthine was reported in one McAr-
dle patient.2 In muscle biopsy material increased amounts of adenosine, inosine and 
hypoxanthine in the absence of the normal IMP accumulation after exercise was 
observed in one MADD patient. This increase in purine nucleosides and bases could, 
however, not account for the decrease found in the adenine nucleotide pools, and it 
was suggested that this might be the result of diffusion of the purine nucleosides and 
bases into the vasculature.3 
This communication presents the results of an ischaemic exercise test with 
measurement of adenosine, inosine, and hypoxanthine in the venous return of the 
forearm in seven control subjects, five MADD patients and six McArdle patients. 
SUBJECTS AND METHODS 
The controls (four males, three females, age 22-52 years) were healthy volunteers 
without any complaint. The diagnosis in the MADD patients (five males, age 14-67 
years) and the McArdle patients (two males, four females, age 8-37 years) was 
confirmed by histochemical and biochemical deficiency of myoadenylate deaminase 
and myophosphorylase, respectively. Additionally, a normal increase of plasma 
lactate and a subnormal increase of plasma NH, concentrations after ischaemic 
forearm exercise was found in each of the MADD patients, whereas a normal increase 
of plasma NH, and a subnormal increase of plasma lactate was found in each of the 
McArdle patients. 
The control subjects, MADD patients and McArdle patients were subjected to a 
standardized ischaemic isometric forearm test as described earlier.4 Blood samples 
were taken before and immediately after the test and at 3,5,7,9,11,15, and 20 
minutes. By means of an indwelling catheter in the antecubital vein, 1.3 ml of blood 
was collected into 5 μΐ of heparin (500 i.u./ml) and 13 μΐ of 1 mmol/1 deoxycoformycin 
(Warner-Lambert, Detroit, MI, U.S.A.), and immediately centnfuged at 9000 g for 
1.5 minute. The plasma was collected and stored in liquid nitrogen without delay. The 
following extraction procedure was carried out at 40C. After thawing, 400 μΐ of 
plasma was deproteinized with 100 μΙ of 2 mol/1 HCI0 4 , and centnfuged at 6000 g for 
3 minutes. Then 250 μΐ of the supernatant was neutralized with 45 μΐ of 3 mol/1 
KHCO3 and again centnfuged at 6000 g for 3 minutes. The neutrah/.ed supernatant 
was analysed by high performance liquid chromatography using the method de­
scribed by Hartwick et al.' 
The data were evaluated statistically by the one-way analysis of variance accord­
ing to Kruskal-Walhs. When the variance analysis yielded significant differences the 
Wilcoxon rank sum test for two groups was performed. The Dixon test was applied to 
show significant differences within a group. Ρ values for two-tailed testing are given. 
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RESULTS 
Table 1 presents the plasma concentration at rest, the maximal concentrations 
after exercise, the differences between these values, i.e., the increase in plasma 
adenosine (AAdo), inosine (ΔΙηο), and hypoxanthine (ΔΗχ) induced by muscular 
work, and the Ρ values calculated according to Kruskal-Wallis. No significant Ρ 
values were found with regard to all the plasma concentrations at rest, the maximal 
adenosine concentrations after exercise and AAdo, but significant Ρ values were 
found with regard to the maximal inosine concentrations and ΔΙηο, as well as the 
maximal hypoxanthine concentrations and ΔΗχ. 
The Wilcoxon test showed significant differences of ΔΙηο and ΔΗχ between 
MADD patients and controls (P = 0.003, Ρ = 0.003). The ranges of the ΔΙηο values 
Table 1. hffect of ischacmic forearm exercise on plasma purine nucleoside and base concentrations 
I'lnsma adenosine (Ado), inosine (Ino) and hypoxanthine (Hx): concentrations at rest, maximal con­
centrations after ischaemic forearm exercise, the differences between these values (all expressed in μιηοΐ/ΐ) 
in controls, myoadcnylate deaminase deficient (MADD) patients and McArdle patients, and I' values 
calculated by the one-way analysis of variance according to Kruskal-Wallis. 
Age Sex At rest Maximal value 
(years) after exercise 
Ado Ino Hx Ado Ino Hx AAdo ΔΙηο ΔΗχ 
Controls 
1 52 M 
2 29 M 
3 22 F 
4 23 F 
5 33 F 
6 34 M 
7 32 M 
Median 32 
MADD| 
1 
2 
3 
4 
5 
Median 
McArdle 
1 
2 
3 
4 
5 
6 
Median 
patients 
47 
24 
67 
14 
29 
29 
: patients 
19 
37 
27 
8 
24 
14 
24.5 
M 
M 
M 
M 
M 
F 
M 
F 
F 
M 
F 
/' 
2.3 
0.2 
0.0 
0.0 
0.0 
0.2 
0.4 
0.2 
0.4 
0.5 
0.6 
0.6 
0.6 
1.1 
0.9 
0.6 
4.0 
1.7 
1.6 
0.6 
0.6 
1.3 
0.9 
1.3 
0.9 
0.9 
0.7 
1.1 
0.4 
0.9 
0.0 
0.4 
0.2 
0.2 
0.9 
0.2 
0.7 
1.1 
0.9 
0.4 
1.1 
0.9 
0.2 
1.3 
1.1 
1.1 
0.4 
0.2 
0.75 
0.7 
0.4 
0.4 
0.9 
0.7 
0.2 
0.55 
0.4 
0.2 
0.7 
0.7 
0.4 
1.0 
0.55 
0.12 0.16 0.08 
2.0 
0.6 
0.0 
0.0 
0.0 
1.5 
0.9 
0.6 
6.7 
17.8 
11.7 
15.6 
9.2 
4.4 
8.7 
9.2 
35.2 
38.5 
27.2 
25.6 
24.3 
32.9 
40.5 
32.9 
6.1 
1.7 
3.9 
2.6 
0.4 
2.6 
0.4 
0.9 
0.9 
1.3 
0.9 
0.9 
9.4 
8.7 
8.3 
6.3 
10.4 
8.7 
0.4 
1.3 
2.2 
1.3 
0.4 
0.5 
0.9 
4.4 
5.9 
17.6 
3.5 
11.7 
39.4 
8.8 
28.5 
31.5 
40.5 
24.8 
42.0 
56.5 
36.0 
0.09 0.006 0.00 
-0.3 
0.4 
0.0 
0.0 
0.0 
1.3 
0.5 
0.0 
6.3 
17.3 
11.1 
15.0 
8.6 
3.3 
7.8 
8.6 
31.2 
36.8 
25.6 
25.0 
23.7 
31.6 
39.6 
31.2 
5.2 
0.8 
3.2 
1.5 
0.0 
1.5 
0.4 
0.5 
0.7 
1.1 
0.0 
0.5 
8.7 
7.6 
7.4 
5.9 
9.3 
7.6 
0.2 
0.0 
1.1 
0.2 
0.0 
0.3 
0.2 
3.7 
5.5 
17.2 
2.6 
11.0 
39.2 
8.25 
28.1 
31.3 
Í9.8 
24.1 
41.6 
55.5 
35.5. 
0.10 0.006 0.004 
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were 0.4-1.3 μιτιοΐ/ΐ and 4.4-17 8 цтоі/і and the ranges of the Δ Η χ values were 6.3-
10.4 цтоі/і and 24.3-40.5 μπιοΐ/ΐ in M ADD patients and controls, respectively. 
The ΔΙηο and Δ Η χ reached the highest values in McArdle patient no. 6. I he 
Dixon test showed that this patient differed significantly from the other McArdle 
patients in ΔΙηο {Ρ < 0.01) but not in ΔΗχ (Ρ < 0.1). However, including or 
omitting the data from McArdle patient no. 6, no significant differences of ΔΙηο and 
ΔΗχ were found between McArdle patients and controls (P > 0.1, Ρ > 0.1). 
DISCUSSION 
NH, is liberated in both the myoadenylate deaminase catalysed conversion of 
AMP to IMP and the adenosine deaminase catalysed conversion of adenosine to 
inosine. Consequently, inosinc and hypoxanthine cannot be derived from AMP 
without NH, production. The subnormal plasma NH, increase shown earlier by 
Fishbein et al.6 in MADD patients is, therefore, consistent with the subnormal plasma 
hypoxanthine elevation demonstrated by Patterson et al.,1 and with our present 
findings. We were particularly interested in plasma adenosine concentrations because 
of the possibility that in myoadenylate deaminase deficiency AMP might be removed 
from the exercising muscle predominantly in the form of adenosine. For that reason 
we added deoxycoformycin to the blood samples in order to inhibit the conversion of 
adenosine to inosine by the adenosine deaminase reaction in whole blood. Even so in 
the MADD patients only a slight increase of plasma adenosine was found in response 
to ischaemic exercise (Table 1). 
We should, however, take into account that by the determination of venous 
effluent concentrations we do not obtain a true picture of the production and release 
of metabolites by the working muscle. In that case one should also measure blood 
flow and arteriovenous differences. No attempt has been made to measure flow 
changes, but the comparable increase of lactate in controls and MADD patients after 
the exercise test suggests that the subnormal increase of inosine and hypoxanthine in 
MADD patients is probably not due to differences of the blood flow between controls 
and MADD patients. The absence of significantly increased adenosine concentrations 
in our MADD patients as compared with the controls might be explained by dimin­
ished ATP breakdown as reported by Sabina et al.7 in three out of four MADD 
patients. Another possibility is the uptake of adenosine by endothelial cells.8 
Our results confirm and extend the observations of Patterson et al.' and Brooke 
et al.2 Besides a subnormal hypoxanthine response there was also a subnormal inosine 
response to ischaemic exercise in the MADD patients. A very high increase of inosine 
and hypoxanthine was measured in one McArdle patient, but a wide variation of 
these values was found in the McArdle patient group (Table 1). The measurement of 
plasma inosine and hypoxanthine before and after ischaemic exercise might be of 
value in the diagnosis of myoadenylate deaminase deficiency, but not in McArdle's 
disease. 
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SUMMARY 
1. Muscle biopsies were taken from 10 control subjects and 5 AMP deaminase 
(AMPD) deficient individuals before and after an ischaemic isometric exercise test 
and analysed for purine nucleotide, NAD', creatine phosphate (CP) and lactate 
content. 
2. The decrease of ATP induced by the exercise test was significantly lower in the 
AMPD deficient patients than in the controls, but the decrease of creatine phos­
phate and the increase of lactate were not different. 'I here were no significant 
differences in the exertional performance level between patients and controls and 
no evidence was obtained of an increased energy expenditure per unit of perfor­
mance in AMPD deficiency. 
3. The AMPD deficient individuals were equally capable to maintain a high adenyl­
ate energy charge (EC) as the control subjects, which indicates a normal regulation 
of the balance between ATP consumption and Al Ρ regeneration. 
4. ATP, ADP and total adenine nucleotide (TAN) but not AMP, were significantly 
elevated in the AMPD deficient patients as compared to the controls before as well 
as after the exercise test. This underlines the role of AMPD activity in the adenine 
nucleotide catabohsm of skeletal muscle. 
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INTRODUCTION 
Although AMP deaminase (AMPD, EC 3.5.4.6.) activity in skeletal muscle was 
discovered in the twenties and its absence was described for the first time as a 
coincidental finding in a case of periodic hypokalaemic paralysis in 1964,1 it was not 
until 1978 that the deficiency state for this enzyme was thought to be associated with 
exercise intolerance.2 Early fatiguabihty and exertional myalgia are considered to be 
the most prominent features of AMPD-deficiency.M 
'logether adenylosuccinate synthetase and -lyase and AMPD constitute the 
purine nucleotide cycle of which one important proposed function is the deamination 
of AMP (Fig. 1) in order to stabilize the adenylate energy charge during periods of 
ATP hydrolysis by pulling the adenylate kinase reaction towards ATP production.''6 
ATP + '/> ADP 
The concent of the adenylate energy charge (EC = . _ „ -rrr . . . „ ) has been 
1
 ATP + ADP + AMP 
introduced by Atkinson6 and is thought to be a metabolic regulatory parameter 
especially in the regulation of the interaction between ATP regeneration and processes 
that consume ATP. In those situations where ATP utilization exceeds the resynthesis 
of ATP e.g. under ischaemic conditions, AMP deamination will occur/ The de-
nominator of the EC is the size of the total adenine nucleotide pool (TAN = ATP + 
ADP + AMP) and can only decrease by the conversion of AMP. 'I wo separate 
pathways are possible (Fig. 1): deamination to IMP by the activity of AMP deaminase 
or dcphosphorylation to adenosine by the activity of 5'-nucleotidase.1* 
Sabina et al.9 suggested that in the AMPD deficient muscle a lower capacity for 
energy production might be the cause of the clinical symptoms. They calculated that 
during a dynamic exercise test the median decrease in total phosphagen (i.e. ATP plus 
creatine phosphate) per unit of work in the AMPD-deficient patients was fivefold 
greater than in the control group. In their study however, they did not take into 
account the turnover of ATP associated with aerobic and anaerobic metabolism. 
Under non-ischaemic conditions such as during a dynamic exercise-test the aerobic 
and anaerobic ATP synthesis is partly derived from the breakdown of blood borne 
substrates and partly from the breakdown of muscle glycogen. 
The present study was undertaken to look for a possible derangement in AMPD-
deficiency of the adenine nucleotide metabolism which among others could be 
reflected by a change in the EC and, additionally, to see whether AMPD-deficient 
patients are facing a reduced energy economy. This paper reports on an ischaemic 
isometric exercise test and the levels of purine nucleotides, creatine phosphate and 
lactate assayed in muscle biopsies obtained before and after exercise from 5 AMPD-
deficicnt individuals and 10 control subjects. Ischaemic conditions were adopted in 
order to minimize the ATP production associated with aerobic metabolism, to 
minimize the loss of lactate from the exercising muscle, and to prevent the resynthesis 
of creatine phosphate after muscle exertion. 
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Figure 1. Metabolic pathways involved m the purine nucleotide cycle and the purine nucleotide cataboltsm. 
MATERIALS AND METHODS 
Subjects. 15 Subjects from whom informed consent had previously been obtained 
were involved in this study: 5 AMPD-deficient patients (4 males, age 24-48 years and 
1 female, age 20 years) and 10 healthy volunteers (5 males, age 29-40 years and 5 
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females, age 23-33 years). The experimental protocol was approved by the committee 
of experimental research on human beings of the University of Nijmegen. After 
suspicion had been raised by the results of a standardized ischaemic forearm test10 
diagnosis of AMPD-deficiency was in all patients confirmed by histochemical and 
biochemical study of muscle biopsy material. All underwent this forearm test because 
of exercise intolerance. The residual AMPD-activity in these patients was less than 
3% of the normal mean. Light microscopy and routine histochemical staining re-
vealed no gross abnormalities except the absence of the AMPD. As a group the 
healthy volunteers were not especially well trained for this study but most of them 
regularly did some form of physical activity. Patient no. 3, an amateur motorcyclist, 
participated in an exercise program twice a week with muscle strength and endurance 
training. 
Ischaemic isometnc exercise test. The subjects were seated upright in a chair with the 
lower leg dependent and the knee flexed to 90°. The pelvis was secured by an 
adjustable belt. They were instructed to perform a voluntary isometric contraction 
with the knee-extensors at a force level of 50% maximal voluntary contraction force 
(MVC) until exhaustion, defined as a failure to hold the target force. This level has 
been chosen because it is known that peak accumulation of lactate by fatigue in 
isometric exercise occurs at 30 — 60% MVC.11 The force generated by the knee-
extensors was measured with a straingauge dynamometer secured just proximal to 
the malleoli and directly shown on a strip chart recorder in front of the subject. To 
quantitate the performance delivered, the impulse (I), that is the integral of force and 
time (Newton x mm) of the quadriceps contraction was measured with a Kipp (Delft, 
The Netherlands) BC-1 integrator. The MVC was determined in three trials, inter-
spaced by 1 minute, whereby the highest value which the subject could sustain for 1 
second, was taken as the maximal voluntary contraction force. After a rest of 10 
minutes local anaesthesia (1% Marcarne, Astra Pharmaceutics Rijswijk, The Nether-
lands) of the skin at the biopsy site, followed by incision was accomplished. A muscle 
sample was taken from the lateral part of the M. Quadriceps Femons, with a modified 
Bergstrom needle. The biopsy material was removed from the needle with a forceps 
and immediately plunged into liquid nitrogen. The same procedure was repeated after 
exercise. The time that elapsed between the insertion of the needle at the end of 
exercise and freezing of the sample ranged from 15 to 25 sec. Ischaemia was brought 
on one minute before the start of the exercise by inflating a cuff arond the upper leg to 
240 mm Hg which was deflated after the post-exercise biopsy had been taken. 
Metabolite analysis. The frozen biopsy material was weighed, homogenized with ice 
cold 0.5 mol/1 HC104 which was added in an amount such as to obtain a 10% W/V 
concentration, and centnfuged at 600 g for 5 minutes at 40C. The supernatant was 
neutralized with 3 mol/l KHCO, and stored at -20 oC. 
ATP, ADP, AMP, IMP and NAD+ in the neutralized supernatant were assayed by 
high performance liquid chromatography. A Spectra Physics (Santa Clara, California, 
USA) SP 8700 liquid Chromatograph thermostated at 40oC equiped with a solvent 
programmer and a Rheodyne injection was used. The detector was a Spectra Physics 
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SP 8300 with a fixed wavelength of 254 nm. The signals were integrated electronically 
with a Spectra Physics SP 1400. A Chrompack (Middelburg, The Netherlands) 
Pellicular reverse phase precolumn (7. S Χ 0.21 cm) was used and separation achieved 
on Chrompack μ-Bondapack С 18 column (30 x 0.46 cm) by a modification of the 
method described by Schweinsberg and I oo.1 2 The column was eluated starting with 
100% 0.1 mol/1 Κ,ΗΡΟ/ΚΗ,ΡΟ, buffer pH 6,25 at a flow rate of 0.6 ml/minute. At 
the time of injection of the sample, a linear gradient was started with methanol at a 
rate of increase of 1.5% methanol/minute until a concentration of 25.5% methanol 
was reached. 
Creatine phosphate (CP) and lactate in the neutralized supernatant were mea­
sured by isotachophorcsis as described earlier." Instrumentation was a LKB (Stock­
holm, Sweden) Tachophor and a Kipp recorder. 
The results of the measurements of purine nucleotides, CP and lactate were 
normalized to muscle NAD' content in order to decrease the variability due to 
differences in the composition of the muscle tissue obtained by muscle biopsy.14 The 
energy (E) consumed in the ischaemic test procedure was calculated as the sum of the 
decrease in ATP and CP plus the increase in lactate multiplied with λΙι because the 
production of 1 mole lactate from glycogen yields 1 l/z mole ATP. 
Statistical analysis. The data were evaluated statistically by the two-way analysis of 
variance. P-values < 0.05 were considered significant. 
RESULTS 
The results are summarized in the Fables 1 - 3 . 
The two-way analysis of variance showed a significantly higher maximal voluntary 
contraction force (MVC) and impulse (I), but not endurance time (T), in the AMPD 
deficient and control males as compared to the AMPD deficient and control females 
(Table 1). These parameters were not significantly different in the AMPD deficient 
males and female as compared to the control males and females. 
Skeletal muscle ATP, ADP and TAN, but not AMP, were significantly higher in the 
AMPD deficient males and female than m the control males and females before as well 
as after the exercise test (Table 2), while no differences were found between the 
AMPD deficient and control males as compared to the AMPD deficient and control 
females. The IMP content, however, was significantly lower in the AMPD deficient 
males and female than in the control males and females before but not after exercise, 
and no difference was found between the AMPD deficient and control males as 
compared to the AMPD deficient and control females. The EC was very slightly but 
significantly higher in the AMPI) deficient and control males than in the AMPD 
deficient and control females before but not after exercise. There was, however, no 
significant difference between the AMPD deficient males and female as compared to 
the control males and females. Differences between the AMPD deficient males and 
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Table 1. Ischaemic isometric exercise test: age, sex, maximal voluntary contraction force (M V'Q, impulse 
(I) and endurance time (T) in the controls and the AMP deaminase deficient patients. The Ρ values were 
calculated by the two-way analysis of variance (P * ¡s related to the control males and females versus the 
AMPD deficient males and female and Ρ * * to the control and AMPD deficient males versus the control and 
AMPD deficient females). 
Controls 
I 
2 
? 
4 
S 
Median 
6 
7 
8 
9 
10 
Median 
Patients 
I 
2 
3 
4 
Median 
S 
Age (yrs) 
40 
29 
30 
34 
Ì6 
Ì4 
23 
U 
23 
23 
27 
23 
Age (yrs) 
48 
31 
24 
16 
34 
18 
Sex 
M 
M 
M 
M 
M 
F 
h 
F 
F 
F 
Sex 
M 
M 
M 
M 
F 
M VC 
699 
737 
768 
711 
729 
719 
493 
S12 
401 
386 
411 
411 
M VC 
4 SO 
56 î 
2016 
607 
585 
362 
(Newton) 
(Newton) 
1 (Newton.min) 
. Ш 
356 
520 
ill 
191 
Ш 
204 
218 
164 
264 
24Ä 
204 
1 (Newton.min) 
171 
211 
460 
141 
276 
222 
Τ (sec) 
67 
M 
82 
54 
66 
66 
Í0 
62 
53 
58 
74 
S8 
Τ (sec) 
SO 
47 
S6 
61 
SI 
91 
l" 0.1 S71 0.2693 0.9220 
I " " 0.0025 0.0076 0.S218 
female and the control males and females or between the deficient and control males 
and the AMPD deficient and control females were not detected with respect to skeletal 
muscle CP and lactate. 
The ischaemic isometric exercise test caused a small but significantly lower decrease 
of ATP in the AMPD deficient males and female as compared to the control males and 
females (Table 3), but the decrease of CP and the increase of lactate were not different. 
The energy expenditure per unit of performance (E/I) calculated from the decrease of 
ATP and CP and the increase of lactate, was not found to be significantly higher in the 
AMPD deficient males and female than m the control males and females. No dif­
ferences were detected between the AMPD deficient and control males as compared to 
the AMPD deficient and control females with any of these parameters. 
DISCUSSION 
In order to study the metabolism of skeletal muscle at work one can choose 
between a dynamic i.e. isotonic exercise test or an isometric exercise test, and also 
between ischaemic or non-ischaemic conditions. Independently of the test situation 
chosen, ATP is the ultimate energy source for contraction but it has to be continuously 
resynthesized. Various ways for the resynthesis of ATP are possible depending on the 
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OS Table 2 Skeletal muscle purine nucleotides (A 1P, ADP, AMP, IMP), total adenine nucleotides (TAN) creatine phosphate (C P) and lactate concentrations (all 
expressed m nanomoielnanomole NAD ' J, and the adenylate energy charge (t CJ before and after exercise in controls and AMPD deficient patients Í he Ρ values 
were calculated by the two-way analysts of variance (P J is related to the control males and females versus the AM PD deftc tent males and female, and Ρ * * to the 
control and AMPD deficient males versus the control and AMPD deficient females) 
Contr 
Median 
6 
7 
8 
9 
10 
Median 
Sex 
M 
M 
M 
M 
M 
ATP ADP AMP TAN te IMP CP 
1 4 . 2 - 8,9 
1 2 . 3 - 9,9 
12,3-11,6 
1 2 , 3 - 11,9 
12,S- 12,2 
2,00-
1,43-
1,J8-
1,45-
1,81 
1,90 
1,47 
2,95 
1,76 
1,91 
0,01 -
0,04-
0,09 -
0,08 -
0,01 -
0,10 
0,12 
0,02 
0,07 
0,03 
16,21 -
l î , 7 7 -
13,97-
13,8?-
14,62 -
10,9 
11,49 
Ш7 
13,73 
14,24 
0 94-
0 95-
0 94-
0 94-
0 94 
0 90 
0 93 
0 9 ? 
0 9 ? 
0 9? 
0,30-
0,22-
0,12 • 
0,18 
0,2 Í -
5,61 
1,94 
0,46 
0,81 
0,7Î 
50,1 -
58,2-
57,9-
48,2-
5?,4 
8,6 
12,7 
10,7 
20,3 
29,9 
12 ,3 -21 ,6 1 ,58-1 ,90 0 , 0 4 - 0 , 0 7 13 ,97-13,57 0 9 4 - 0 9 3 0 ,22-0 ,81 53,4 10,7 
13 ,4 -11 ,9 
12.2 - 10,3 
12.3 - 9,6 
1?,1 - 11,9 
13,1 - 11,4 
1,81-
1,86-
1,82 
1,69 
2,89 
1,94 
2,03 
2,04 
2,06 
2,37 
0,00 -
0,03-
0,02 
0,10-
0,00 -
0,02 
0,16 
0,07 
0,03 
0,00 
15.21 -
14,09-
24.22 -
24,79-
25,12 
2 3,86 
22,49 
J),71 
13,99 
13,77 
0 94-
0 93-
0 93 
0 94-
0 94-
0 93 
0 91 
0 91 
0 92 
0 92 
0,?8-
0,2 7-
0,23 -
0,17-
0,00 -
0,50 
1,30 
3.71 
1,19 
1,46 
48,0-
62,4 
54,2 -
52,4 
34,0 
12,7 
8,6 
7,5 
7,2 
4 0 
13,1 - 11,4 2,82-2 ,06 0,01 - 0,03 14,79 - 13,77 0 94 - 0 92 0,17- 2,30 5 1 , 4 - 7,5 
Lactate 
11,4- 87,3 
6 , 2 - 57,3 
5 ,6-40 ,? 
4,1 - 39,5 
6,6 - 34,0 
6 ,2 -40 ,3 
9,2 - 4 0 , 9 
6,1 - 57,0 
11,8 67,5 
4 , 5 - 4 5 , 6 
3,4 -45,1 
6,1 - 4 5 , 6 
Pat Sex ATP ADP AMP ΊΑΝ te IMP CP Lactate 
1 
2 
3 
4 
M 
M 
M 
M 
15,4-15,2 
14,1 - 14,4 
13,8-13,4 
14,1 - 13,7 
2,04-
2,07 
1,73-
1,90-
-2,76 
-2,16 
-2,51 
-2,40 
0,00-
0,04-
0,04-
0,01 -
-0,03 
-0,06 
-0,06 
-0,00 
17,44-17,99 
16,2 -16,62 
15,57-15,97 
16,01 -16,10 
0 94-
0 93-
0 94 
0 94-
- 0 92 
- 0 93 
- 0 92 
- 0 9 3 
0,00 -
0,11 -
0,15 
0,00 -
- 0,00 
-0,13 
-0,14 
- 0,00 
57,9- 6,9 
4 7 , 8 - 11,6 
7 0 , 8 - 7,1 
4 0 , 3 - 6,6 
8,9-
13,0 -
8,8-
5,6-
- 68,6 
- 37,8 
-63,1 
-47,7 
Median 
5 Í· 
14,1 - 14,1 
14,1 - 14,6 
1 ,97-2,46 
2 , 1 6 - 2 , 0 7 
0,02 - 0,05 
0,09 - 0,04 
16,1 - 16,36 
16 ,35- 16,71 
0 9 4 - 0 9 3 
0 93 - 0 94 
0 ,06 -0 ,065 
0 ,09 -0 ,11 
52,9-
57,2-
- 7,0 
-26,1 
8 , 8 - 55,8 
9 ,7 -42 ,9 
0 0022-0 0002 0 0267-0 0152 0 9937-0 3403 0 0022-0 0002 0 6394-0 2726 0 0307-0 0522 0 6487-0 9493 0 1806-0 9688 
0 9363-0 7532 0 0569-0 3615 0 9017-0 7472 0 7047-0 6110 0 0094-0 5876 0 8239-0 7993 0 6843-0 9085 0 8558-0 7284 
type of exercise. During a dynamic non-ischaemic exercise test with increasing work 
loads such as the bicycle test used by Sabina et al.,9 a considerable part of the ATP 
utilized is derived from oxidative phosphorylation especially in the beginning when 
using low loads. It is known that isometric contraction sustained at 20% or more of 
the MVC, impairs the muscle blood flow15 thereby making substantial demand on 
anaerobic metabolism, which will be reflected in the lactate content of the muscle. 
Besides, under this condition predominantly fast-twitch-glycolytic type IIВ fibers will 
be used which have a higher AMPD-activity than the other fibre types.16 We decided, 
therefore, to use an isometric test at 50% MVC to minimize the aerobic and to 
emphasize the anaerobic ATP production, and at the same time to activate especially 
the type IIВ fibers. Additionally we imposed ischaemic conditions arbitrarily starting 
the ischaemic period one minute before the exercise because it is known that after four 
minutes creatine phosphate already tends to decline.17 
The ischaemic conditions imposed during our exercise-test allow a more precise 
estimation of the contribution of muscle glycogen breakdown to the total ATP 
turnover because no or at least a reduced amount of lactate is washed out of the 
exercised muscles. The lactate content of skeletal muscle in the AMPD-deficient 
patients was not significantly different from the lactate content in the controls (Table 
Table 3 Delta values for ATP, creatine phosphate (CP) and lactate (all expressed in nanomolelnanomole 
NAD ) after the ischaemic isometric exercise test, and the calculated energy consumed per unit of 
performance (t/l, expressed in nanomole ATPInanomole NAD'INewton mm) in controls and AMPD 
deficient patients The Ρ values were calculated by the two-way analysis of variance (p * is related to the 
control males and females versus the AMPD deficient males and female, andp** to the control and AMPD 
deficient males versus the control and AMPD deficient females) 
Controls 
1 
2 
3 
4 
S 
Median 
6 
7 
8 
9 
10 
Median 
Patients 
1 
2 
3 
4 
Median 
5 
P" 
P* * 
Sex 
M 
M 
M 
M 
M 
h 
F 
F 
F 
F 
Sex 
M 
M 
M 
M 
F 
AAIP 
- u 
- 2,4 
- 0,7 
- 0,4 
- 0,6 
- 0,7 
- ì,5 
- 1,9 
- 2,7 
- 1,2 
- 1,7 
- 1,7 
AAIP 
- 0,2 
+ 0,3 
- 0,4 
- 0,4 
- 0,3 
+ 0,5 
0 0235 
0 751S 
дет 
- 4 1 , 5 
- 4 5 Д 
- 4 7 , 2 
- 37,9 
- 2 3 , 5 
- 41,4 
- 3 5 , 3 
- 52, S 
- 4 6 , 6 
- 44,2 
- 3 0 , 0 
- 44,2 
ДСР 
- 5 1 , 0 
- 3 6 , 2 
- 6 3 , 7 
- ?3,7 
- 4 3 , 1 
- 3 1 , 1 
0 7337 
0 792S 
ALactate 
+ 75,9 
+ 51,3 
+ 34,7 
+ 3S,4 
+ 27,4 
+ 35,4 
+ 31,8 
+ 50,9 
+ 55,7 
+ 43,1 
+ 41,7 
+ 41,7 
ALactate 
+ 59,7 
+ 24,8 
+ 54,3 
+ 42,1 
+ 48,2 
+ 33,2 
0 7495 
0 6834 
m 
4 80 
3 50 
1 92 
2 94 
1 67 
2 94 
4 14 
Î53 
8 30 
653 
3 80 
5 51 
in 
8 14 
3 46 
3 16 
2 85 
331 
3 62 
0 6570 
0 1130 
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2 and 3), a finding which does not support the suggestion that AMPD-deficiency 
might interfere with the activation of phosphofructokinase by the ammonia produced 
in the AMPD reaction and, therefore, with the stimulation of the glycolysis during 
muscular exertion.18 Our results also show that the AMPD-deficient individuals are 
capable of maintaining their EC at the same high level as the control subjects (Table 
2), indicating a normal regulation of the balance of ATP consumption and ATP 
regeneration during ischaemic isometric exercise. This was also reflected by the 
decrease of skeletal muscle ATP after the exercise which was even lower in the AMPD 
deficient patients than in the controls (Iable 3). A similar finding was reported by 
Sabina et al.4 in 3 out of 4 AMPD deficient individuals using a dynamic exercise test. 
As expected the ischaemic isometric test demonstrated a lower performance level 
in the females as compared to the males (Fable 1). 'I here was, however, no difference 
in performance level between the AMPD deficient patients and the controls in 
contrast to the finding of Sabina et al.' Previously, using a standardized ischaemic 
isometric handgrip test, we also found a normal performance in AMPD deficient 
patients but a subnormal one in myophosphorylase deficient (McArdle) patients." 
This demonstrates that an ischaemic isometric exercise test is capable of discriminat-
ing between patients with different metabolic myopathies on the basis of differences 
between their level of performance. 
If the decrease of skeletal muscle AIT and CP, and the increase of lactate was 
used to estimate the energy expenditure per unit of performance (E/I), then no 
significant difference was found between AMPD deficient individuals and control 
subjects (Table 3). The contribution of the residual aerobic metabolism to the ATP 
turnover under our ischaemic test conditions is unknown. One of the proposed 
functions of the purine nucleotide cycle is the production of fumarate which is an 
intermediate of the tricarboxylic cycle.5 Dysfunction of the purine nucleotide cycle 
caused by AMPD deficiency might result in a reduced amount of fumarate and thus in 
a decreased residual aerobic metabolism in the patients. In that case the underestima-
tion of E/I should be more pronounced in the controls than in the patients, i.e. the 
actual energy expenditure per unit of performance might then be lower in the patients 
than in the controls provided that the limitations imposed by our ischaemic test 
conditions still permit for sufficient residual metabolism. 
The finding of higher skeletal muscle ATP, ADP and TAN concentrations in our 
patients as compared with the controls, before as well as after exercise (Table 2), is in 
agreement with the suggestion that AMPD activity plays an essential role in the 
catabohsm of the skeletal muscle adenine nucleotides.20 Previously, subnormal plas-
ma hypoxanthine20'21 and inosine21 concentrations were found after forearm exercise 
in AMPD deficiency, but the adenosine level was not significantly different.21 In vitro 
incubation studies reported by Sabina et al.' showed no evidence of adenosine 
production in muscle biopsies of controls in contrast to muscle biopsies from AMPD 
deficient patients and inhibition of the adenosine deaminase activity by 
2-deoxycoformycine reduced the inosine- and hypoxanthine formation in AMPD 
deficient muscle biopsies but not in control muscle biopsies. These observations 
demonstrate that although the conversion of AMP to adenosine, inosine and hypox-
anthine is possible in skeletal muscle, the catabohsm of adenine nucleotides normally 
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involves conversion of AMP to IMP, inosine and hypoxanthine (Fig. 1). These 
observations also contradict another proposed function of the purine nucleotide 
cycle, that of preserving the purine nucleotide content of skeletal muscle through the 
accumulation of IMP during muscular exertion, thereby preventing the degradation 
of AMP to adenosine, inosine and hypoxanthine and the diffusion of these com-
pounds out of the cell into the vasculature.22 
The skeletal muscle IMP in our patients was significantly lower as compared to 
the controls before exercise. The difference after exercise was not significant (P = 
0.052) due to the wide range of values obtained. Nevertheless, the tendency of only a 
small or even no increase of IMP in the patients was obvious (Table 2). Although the 
average increase in the control subjects was about 7-fold, it was by no means the 70 to 
90-fold increase reported by Dudley and Terjung.16 The high frequency stimulation 
used by them also caused a much larger decrease of TAN (50% versus 11%). The 
reason for this discrepancy could be the different type of exercise. An argument in 
favour of this supposition was provided by Edwards1' who stated that depletion of 
energy substrates is not the limiting factor for duration of sustained voluntary 
isometric contractions. 
The results of our study show that AMPD deficiency is not associated with an 
impaired energy economy during ischacmic isometric exercise. The possibility of a 
subnormal aerobic metabolism as a consequence of the failure to produce a sufficient 
amount of fumarate by the purine nucleotide cycle and, therefore, reduced ATP 
production during non-ischaemic isotonic exercise has not been investigated. Re-
cently, however, Fishbein et al.23 referred to the preferential association of AMPD 
with the sarcoplasmic reticulum and a possible role of the enzyme in the functioning 
of the calcium pump in the sarcoplasmic reticulum, the study of which might provide 
more insight in the pathophysiology of AMPD-deficiency. 
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Chapter VI 
MYOADENYLATE DEAMINASE DEFICIENCY: 
A CLINICAL, GENETIC AND BIOCHEMICAL STUDY IN NINE FAMILIES 
S. P. T. Sinkeler, E. M. G. Joosten, R. A. Wevers, T. L. Oei, Α. E. M. Jacobs, J. H. 
Veerkamp and В. С. J. Hamel 
MUSCLE & NERVE (SUBMITTED) 
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SUMMARY 
The clinical significance of myoadenylate deaminase (MAD) deficiency and its 
mode of inheritance are still questioned. Thirty-six relatives of 9 unrelated MAD-
deficient patients were examined with the aid of a standardized ischemic forearm test. 
Eight new cases of MAD-deficiency were detected, 5 of which were confirmed 
histochemically and biochemically. Obligate heterozygotes showed a normal am-
monia production and MAD-staining, but the mean activity of the enzyme was 
significantly less than in a group of controls. The results obtained from the family-
study strongly suggest an autosomal recessive mode of inheritance. However, only 2 
of the 8 newly found MAD-deficient individuals complained of exertional myalgia 
while the remaining 6 were without any symptoms or complaints. This finding casts 
doubt on the clinical significance of MAD-deficiency and the relationship of the 
deficiency state with exertional myalgia. 
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INTRODUCTION 
In accordance with the proposed role of myoadenylate deaminase (MAD) in 
purine metabolism,11 one would expect the complaints of deficient patients to be 
related to exercise. Exertional myalgia, fatigue and muscle pain, usually beginning in 
adult life, indeed are often mentioned2'' In some cases even exertional rhab-
domyolysis has been described.29·16 
However, complaints of exercise intolerance are rather common and unspecific, 
and in routine muscle biopsy scries the deficiency of MAD is often detected (1-2% of 
muscle biopsies).2 The association of MAD-deficiency with clinical complaints of 
exercise intolerance could therefore be coincidental, hurthermore, in about half the 
cases the deficiency is associated with other neuromuscular diseases.2 It is not clear 
whether this is chance association or whether there is a MAD-deficiency secondary to 
the associated neuromuscular diseases. Consequently, several authors" 1416 question 
the clinical significance of the deficiency. The problem is further complicated by the 
fact that also symptomatic heterozygotes16"9 are described, and even asymptomatic 
homozygotes without exercise-related complaints.2 9 Although the frequency of oc-
currence of MAD-deficiency in muscle biopsy series is well known, there are no 
figures available about the prevalence in the general population. If MAD-deficiency is 
indeed only a harmless variant, then the occurrence in the population will be the same 
as in biopsy series. Kelemen et al.9 found a frequency of 8 3% of MAD-deficiency in 
biopsies of patients with exertional myalgia, a frequency which was significantly 
higher than in the remaining biopsies in his series. This could point to a clinical 
significance of the deficiency and is not compatible with chance association. 
However, others could not confirm these findings " 
The deficiency is probably inherited as an autosomal recessive traiti Sibs of both 
sexes with the deficiency have been described,9,15 and in one family an intermediate 
enzyme activity was reported in both parents of a deficient patient/ But also autoso-
mal dominant inheritance8 9 has been suggested. Fven scx-hnked recessive inheritance 
has been proposed,7 but DiMauro et al.' have provided evidence that in the family 
reported, there was most probably an autosomal recessive inheritance. The aim of the 
present study is to obtain more information concerning the clinical significance of the 
deficiency (do newly diagnosed cases in the family study have exertional myalgia, do 
heterozygotes have complaints?) and its genetics. The need for diagnostic muscle 
biopsies could be reduced by the use of a sensitive screening test developed recently.17 
With this screening test the families of 9 patients with MAD-deficiency, who came to 
medical attention with exercise-related complaints without an associated neu-
romuscular disorder, were examined. New cases were detected, which were con-
firmed by histochemical and biochemical investigation of muscle biopsies. The data 
were compared with clinical symptoms and the outcome of a questionnaire on 
complaints. 
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MATERIALS AND METHODS 
Patients and families. 
We examined the relatives of 9 unrelated patients with MAD-deficiency and 
exertional myalgia but without associated neuromuscular disease (Table 1). All 
patients and their relatives gave their informed consent. The investigation had been 
Table 1. hmdings in probands 
Proband of 
family no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Age 
32 
20 
38 
50 
17 
15 
26 
33 
16 
(yrs) Sex 
M 
F 
M 
M 
M 
F 
M 
M 
M 
Complaints 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional rhabdom 
exertional myalgia 
yolybis 
Residual MAD-
activity ( % 
mean) 
1.3% 
1.3 % 
< 1 % 
1.6 % 
< 1 % 
15.1 % 
< 1 % 
< 1 % 
1.7 % 
con trol 
Age (yrs) at time of 
onset of complaints 
25 
3 
37 
42 
8 
14 
13 
31 
12 
approved by the ethical committee of the St. Radboud Hospital. The residual MAD-
activity in the muscle biopsy of the proband of family 6 was unusually high but 
because of the results of the ischemic exercise test and the absence, histochemically, of 
MAD-activity, she was included in the study. The proband of family 8 was seen 
because of severe rhabdomyolysis, his history gave evidence of exertional rhab-
domyolysis. In all probands MAD-deficiency was histochemically and biochemically 
confirmed after suspicion had arisen in the ischemic exercise test. 36 Relatives 
(parents, spouses, sibs and children, Fig. 1) of our probands could be investigated with 
the aid of the standardized ischemic exercise test previously described;17 only II 2 of 
family 7 could not be tested. Subsequently, from 6 out of 8 cases suspected of MAD-
deficiency a needle biopsy was taken to confirm the diagnosis histochemically and 
biochemically. Additionally, 8 out of 20 obligate heterozygotes, (an autosomal 
recessive inheritance being assumed), underwent a needle biopsy to biochemically 
determine MAD-activity. All relatives had completed a questionnaire on exercise-
related complaints, before the results of the exercise test were known. These question-
naires were rated blindly by one of the authors as evident, possible or no exercise-
related complaints. 
Biochemical studies. 
MAD-activity was assayed in needle-biopsies of M. Quadriceps, essentially 
according to Leech and Newsholme,l0 by radiochemically following the conversion of 
[8- l 4C] AMP (final concentration 2 mM) to [8- , 4C] IMP. The value for normal 
mean MAD-activity was obtained by measuring enzyme activity in 8 muscle biopsies 
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big Í Pedigrees of 9 myoadenylate deaminase deficient patients 
which showed no abnormalities on histochemical examination. Protein content was 
determined according to the method as described by Lowry et al.12 The tissues were 
analyzed for histochemical MAD-activity with the technique described by Fishbein et 
al.4 
RESULTS 
New MAD-deficiency cases. By means of the ischemic exercise test 8 new cases 
were found to be suspect of MAD-deficiency (Fig. 2). This was subsequently con-
firmed histochcmically and biochemically in most cases (Fig.l and Table 2). In all 
cases studied, the results of the exercise test were consistent with these histochemical 
and biochemical data. 
Genetic aspects. The new MAD-deficient cases were of both sexes (3 females and 
5 males). In 7 out of 9 families the deficiency occurred only in sibs of the proband but 
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hig.Z. The results of the ischemic exercise test m 36 relatives of the 9 MAD-deficient index-cases. Symbols 
are given in figure 1, the line discriminates between MAD-deficiency and non-MA D-deficiency (bmkeler et 
al.П 
in two the deficiency state was found in successive generations (Family 1 and 2, Fig. 
1). The deficiency occurred in 4 out of 11 sibs of probands with parents who were 
both thought to be heterozygotes (Family 1, III 1 and III 2, Family 2 and Family 4 were 
excluded). With the assumption that cases II 1 of Family 1 and I 1 of Family 2 are 
heterozygotes, the findings are compatible with an autosomal recessive trait. Enzyme 
activity in II 1 of Family 1, was more than 2 SD lower than the mean activity in 
controls, and in I 1 of Family 2, more than 1 SD. 
Obligate heterozygotes. Because of the fact that the pedigrees shown can only be 
explained by an autosomal recessive inheritance, it is possible to designate 20 obligate 
heterozygotes. Obligate heterozygotes could not be detected with the exercise test 
since they showed a normal increase of ammonia after exercise (Fig. 2). Their muscle 
biopsies showed a normal MAD-staining. With the biochemical assay the mean 
MAD-activity in heterozygotes, 293 ± 57 nmol.min.— ' per mg. protein (range 221-
397, N = 8) was found to be significantly lower than the mean activity in the controls, 
443 ± 95 nmol.min.-1 per mg. protein (range 321-624, N = 8) (P < 0.01, Wilcoxon 
rank sum test). Individual heterozygotes could often not be designated due to the large 
standard deviation of the mean control value. 
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Complaints in new homozygotes and heterozygotes. Only 2 of the 8 new MAD-
deficiency cases had complaints, as well as 5 of the 20 obligate heterozygotes (Table 
2). None of the remaining 8 relatives, who are neither homozygotes nor obligate 
heterozygotes and among whom, possibly, some heterozygotes are present, had 
exercise-related complaints. Tabic 1 shows that in about half the cases of the pro-
bands (4/9) the MAD-deficiency did not present symptoms until adulthood, whereas 
it is evident from Table 2 that 5 out of the 8 newly found deficient individuals are still 
in their second decade. 
Table 2. bindings in new cases of MAD-defiaency and obligate heterozygotes. 
Pam. No. Age (yrs) Sex Com- Age (yrs) at time of MAD- Residuili MAD 
plaints onset of complaints stain activity (% 
control mean) 
a. new deficiency cases: 
1, 
1, 
2, 
2, 
2, 
Î, 
5, 
9, 
II 2 
1112 
12 
II 2 
11 3 
II 1 
II 3 
II 3 
35 
11 
52 
18 
14 
43 
9 
14 
F 
l·' M 
M 
F 
M 
M 
M 
+ 
-
-
+ 
-
-
+ 
-
b. obligate heterozygotes 
1, 
1, 
1, 
1, 
2, 
3, 
\ 
4, 
4, 
4, 
4, 
5, 
s, 
6, 
6, 
7, 
7, 
8, 
9, 
9, 
I 1 
I 2 
II 1 
III 1 
I 1 
I 1 
12 
II 1 
II 2 
II 3 
11 4 
I 1 
12 
I 1 
12 
1 1 
12 
12 
I 1 
I 2 
58 
63 
38 
14 
46 
70 
70 
14 
19 
21 
22 
44 
48 
44 
41 
50 
56 
74 
42 
4Î 
F 
M 
M 
M 
F 
F 
M 
M 
F 
M 
M 
F 
M 
F 
M 
F 
M 
M 
F 
M 
+ 
-
-
-
-
+ 
+ 
-
-
+ 
+ 
-
+ 
± 
+ 
-
-
-
± 
-
n.d. = not determined. 
MAD-activity of controlb: 443 ± 95 nmol.mm ' per mg. protein 
(Ν = 8, range 321-624). 
DISCUSSION 
As is shown by this family study (Table 3) only a minority of the newly diagnosed 
M AD-deficient family members and of the obligate heterozygotes have complaints of 
12 
12 
absent 
absent 
n.d. 
absent 
absent 
n.d. 
absent 
absent 
present 
present 
present 
n.d. 
present 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
present 
present 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
present 
present 
< 1 % 
< 1 % 
n.d. 
< 1 % 
< 1 % 
n.d. 
n.d. 
< 1 % 
56 % 
90 % 
5 0 % 
n.d. 
73 % 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
65 % 
5 6 % 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
66 % 
7 5 % 
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Table 3. The relation of MAD-deftctency with exercise-related complaints. 
Generic state hvident complaints Possible complaints No complaints 
New homozygote 2 1 5 
Obligate heterozygote 5 4 11 
Not homozygote or obligate 
heterozygote 0 4 4 
exertional myalgia. The complaints put forward had not been severe enough for them 
to call in medical attention. These complaints were not present in family members 
who were neither homozygotes nor obligate heterozygotes. From our findings it is 
evident that MAD-deficient individuals often do not have complaints. It should be 
mentioned, however, that it is not uncommon for MAD-deficient subjects to start 
getting complaints in adulthood. ' Also in our probands (Table 1 ) this can be observed, 
but 5 out of 9 probands already had complaints in their first or second decade. From 
our 6 new deficiency cases without complaints, 4 are in their second decade (Table 2). 
It is possible that some of them will develop exercise-related complaints in the future, 
but it is unlikely that all will get complaints, taking into account that half of our 
probands complained of exertional myalgia already in their first or second decade. 
So our family study does not demonstrate an evident relation between exercise-
induced complaints and the deficiency state. Only part of the deficient individuals 
have complaints possibly related to the deficiency. The same considerations do hold, 
in our opinion, for the heterozygotes. 
MAD-deficiency is reported to be an autosomal recessive defect. The results of 
our family study are compatible with this mode of inheritance. In two families (Fam. 1 
and 2), however, there are deficiency cases in successive generations (Fig. 1). Assum-
ing that family 1, II1 and family 2,11, are heterozygotes, these family trees can also be 
explained with an autosomal recessive mode of inheritance. This assumption is 
supported by the finding of a reduced MAD-activity in the biopsies of these relatives 
(Table 2). The finding of the two families with pseudo-dominant inheritance points to 
a high frequency of heterozygotes in the population; Fishbcin et al.2 calculated on the 
basis of the Hardy-Weinberg law and a frequency of MAD-deficiency in the biopsy 
population of 1-2%, a frequency of heterozygotes of 18-24%. If MAD-deficiency 
should be indeed only a clinically insignificant biochemical finding, then the frequen-
cy of heterozygotes in the general population could be in the same order of magnitude. 
The finding in our family study of two pseudo-dominant inheriting families is in 
accordance with a high frequency of heterozygotes in the general population. The 
assumption of an autosomal recessive mode of inheritance is further supported by our 
finding of a significantly lowered mean MAD-activity in obligate heterozygotes 
compared with controls, as was observed earlier in one family.'' 
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Chapter VII 
MYOADENYLATE DEAMINASE DEFICIENCY: 
CAUSE OF EXERTIONAL MYALGIA OR INCIDENTAL FINDING? 
S. P. T. Sinkeler, E. M. G. Joostcn, T. L. Oei and R. A. Wevers 
MUSCLE & NERVE (SUBMITTED) 
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SUMMARY 
The clinical significance of myoadenylatc deaminase (MAD) deficiency is still 
questioned. Most authors favour the idea of MAD-deficiency being a cause of 
exertional myalgia. Retrospectively, the occurrence of MAD-deficiency in 519 rou-
tine muscle biopsies was determined and compared in a prospective study with the 
prevalence of MAD-deficiency among 217 patients with exercise-related complaints 
in order to see whether MAD-deficiency occurs more frequently in an exertional 
myalgia group, which wasn't the case. A group of healthy volunteers was studied for 
comparison. Recently we reported on 8 newly found MAD-deficient individuals 
among 36 relatives of 9 MAD-deficient patients. Of these 8 MAD-dcfiuent subjects, 
however, only 2 had exercise-related complaints. 
The findings cast doubt on the association between MAD-deficiency and exer-
tional myalgia. 
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INTRODUCTION 
Myoadenylate deaminase (MAD) deficiency was for the first time causally 
related to a metabolic myopathy in 1978 by Fishbein et al.4 In large series of 
consecutive muscle biopsies, executed for a broad spectrum of neuromuscular disor-
ders, the frequency of occurrence of the deficiency ranged from 1 — 2.9% which made 
it the most common known enzyme deficiency of skeletal muscle.J·1011,13,17 Soon after 
the first report it became clear that there were no distinctive clinical features among 
the patients although the majority complained of exercise-related symptoms such as 
fatigue, cramps or myalgias, commonly denoted as 'exertional myalgia'. 
Even though it was not possible to distinguish the disorder from other pathologic 
entities by means of the uncharacteristic and subjective complaints of the patients, in 
ascertaining the clinical significance of the deficiency the functional and metabolic 
abnormalities in MAD-deficiency found by Sabina et al.15 seemed promising. The 
authors concluded from their experiments that patients with MAD-deficiency tire 
more quickly and perform less work than normal controls or other patients with 
exertional myalgia do. As previously described20 and in contrast to these findings, we 
could not find any difference between MAD-deficient patients and controls. Neither 
could we obtain evidence,18 as judged by the purine nucleotide, creatine phosphate 
and lactate content of muscle biopsies before and after exercise, of an increased energy 
expenditure per unit of performance in MAD-deficiency as suggested by Sabina et 
al.15 In other words, the assumption of myoadenylate deaminase deficiency being the 
cause of exertional myalgia or exercise intolerance is still not substantiated. 
Contributing to further confusion is the fact that absence of MAD-activity has 
also been described in patients with a heterogenous group of unrelated conditions, 
such as hypokalaemic periodic paralysis,2 amyotrophic lateral sclerosis," Kugelberg-
Welander syndrome,17 progressive systemic sclerosis,7 facial and limb girdle myopa-
thy14 and so on. Especially Shumate,1617 but also Hayes et al.8 and Heffner9 questioned 
the pathologic significance of MAD-deficiency and suggested that the deficiency was 
an incidental finding or produced symptoms only in concert with other, as yet 
unidentified, abnormalities or circumstances. However, in a retrospective survey of 
302 muscle biopsies, Kelemen et al.11 found 36 biopsies which were performed on 
index cases with myalgia. All these biopsies were investigated with the aid of a 
histochemical MAD-stain.6 MAD-deficiency was significantly more common in this 
exertional myalgia cohort than it was in a group of patients who underwent a muscle 
biopsy for other clinical problems On the basis of these retrospective data, the 
authors admitted a relationship between MAD-deficiency and myalgia. 
The discrepancies between the positive findings of Kelemen et al. concerning the 
clinical relevance of MAD-deficiency based on a rather small group of patients with 
exertional myalgia and our results as mentioned before, prompted us to study 
prospectively the frequency of occurrence of the deficiency-state in a large group of 
patients with exercise-related complaints and in a group of healthy volunteers, in an 
attempt to answer the question whether or not MAD-deficiency is associated with 
exercise-related complaints. 
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SUBJECTS AND METHODS 
Study 1. In the years 1980-1986,519 patients, over 10 years of age who had been 
referred with a broad spectrum of neuromuscular complaints, underwent a muscle 
biopsy. Approximately 30% of the biopsies executed at our institution is from 
patients below the age of 11 and with the majority in the first half of that decade. Since 
these youngsters do not reliably indicate exertional myalgia it seemed more appropri-
ate to exclude them from the study. In family studies (a.o. malignant hyperthermia) 
only the proband was included. From study 1 were also excluded patients with 
exercise-related complaints, because we intended to look for the prevalence in 2 
patient-cohorts: those with exercise-related complaints (study 2) and those without 
(study 1). The muscle tissues were analyzed for histochemical MAD-activity with the 
technique as described by Fishbein et al.6 In the 519 specimens, the intensity of 
staining on gross and microscopic examination was the criterion used for diagnosis. If 
MAD-deficiency was detected histochemically and sufficient biopsy material was 
available, then MAD-activity was assayed biochemically. We did not take into 
account the possibility of secondary deficiencies as suggested by Fishbein et al.' 
because residual MAD-activity was practically absent m most cases. 
Study 2. In the years 1983-1986,217 patients performed a standardized ischemic 
forearm test, as previously described,19·20 because of their exercise-related symptoms. 
In these cases where the test suggested a MAD-deficiency or was equivocal in this 
respect, a biopsy followed in order to substantiate the deficiency histo- and bio-
chemically. Biochemically MAD-activity was measured essentially according to the 
method described by Leech and Newsholme.12 
Study 3. The 78 healthy volunteers consisted of 45 males (mean age 32 yrs, range 
19-55) and 33 females (mean age 30 yrs, range 22-55), mainly hospital personnel and 
medical students. They also performed the standardized ischemic forearm test. 
RESULTS 
Study 1. In the retrospective survey of 519 biopsy specimens, 11 lacked enzyme-
activity histochemically i.e., 2 .1%. The biochemical enzyme-activity was determined 
in 9 cases (Table 1) which all had a residual MAD-activity of less than 6.9% of the 
control mean value (105 nmol/mg protein per hour, range 30-311, N = 20). In the 
remaining 2 patients there was not enough material to determine the enzyme-activity 
biochemically (Table 1). 
Study 2. In the prospective study 217 patients performed the screening test of 
which 10, i.e., 4.6%, produced an insufficient amount of ammonia suggesting a 
MAD-deficiency which was subsequently histochemically and biochemically con-
firmed in all cases (Table 2). 
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Table 1 Eleven retrospeavely found MAD-defiaent patients: some characteristics. 
Pattent nr. 
1 
2 
Ì 
4 
S 
6 
7 
S 
9 
10 
и 
Age (yrs) 
69 
34 
37 
59 
55 
12 
53 
13 
61 
48 
69 
Sex 
M 
M 
M 
M 
M 
M 
t 
M 
M 
F 
F 
Clinical or biopsy finding 
polyneuropathy 
acid maltase deficiency 
dystrophia myotonica 
polyneuropathy 
polyneuropathy 
CK-elevation 
polyneuropathy 
polyneuropathy 
polyneuropathy 
polyneuropathy 
polymyositis 
Residual MAD-
actwity (% control 
mean) 
0.9 
2.0 
6.2 
1.1 
<0.5 
0.8 
6.9 
< 0 . 5 
< 0 . i 
N.D. 
N.D. 
N.D. = Noi Determined 
Table 2. Ten prospectively found MAD-deficient patients with exertional myalgia. 
Patient nr. Age (yrs) Sex Residual MAD-activity 
(% control mean) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
32 
20 
38 
50 
17 
15 
26 
33 
16 
S3 
M 
F 
M 
M 
M 
F 
M 
M 
M 
M 
1.3 
1.3 
< 1 
1.6 
< 1 
15.7 
< 1 
< 1 
1.7 
< 1 
When comparing the prevalence figures in the retrospective study 1 and the prospec­
tive study 2, which are 2.1% and 4.6% respectively, using a Chi2-test, we find that 
these figures are not significantly different (P = 0.11). 
Study 3. In 2 out of 78 healthy volunteers, i.e. 2.6%, the forearm test was 
strongly suggestive of MAD-deficiency. These two male volunteers were aged 25 and 
29 years. They did not have any complaints and both tolerated (prolonged) physical 
exercise well. Also total impulse during the exercise test was normal. 
DISCUSSION 
Up to now the clinical significance of myoadenylate deaminase deficiency is still 
questioned. If the deficiency is not responsible for a definite clinical disease syndrome, 
one would expect the prevalence of this genetic curiosity to be the same in the normal 
population as in muscle biopsy scries.' However, the determination of the prevalence 
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in the general population is clearly not well possible and for that reason did we and 
others approximated this figure by studying a large series of muscle biopsies executed 
for all kinds of neuromuscular complaints but excluding exercise-related ones. 
The 2.1% occurrence of histochcmical absence of MAD in our series is in accordance 
with the prevalence of MAD-deficiency reported by several authors.10'11·"·1" MAD-
deficiency occurred in the exertional myalgia group somewhat more frequently 
(4.6%) than in the routine muscle biopsies (2.1%). The difference, however, does not 
reach statistical significance and so could be due to chance. Our supposition that 
MAD-deficiency occurs m the general population as frequent as in muscle biopsy 
series is encouraged by the finding of 2 deficient subjects out of 78 healthy volunteers 
i.e. 2.6%. It is obvious, however, that this latter cohort is not a representative sample 
of the general population. 
Anyhow, when inspecting the above mentioned findings it becomes doubtful whether 
MAD-deficiency is associated with exertional myalgia. This conclusion is unlike that 
of Kelemen et al.11 The cause of the discrepancy lies mainly in the prevalence figures 
obtained in the exertional myalgia group (3 MAD-deficient patients out of 36 in his 
material versus 10 out of 217 in ours). 
There are several explanations: 
1. it is possible that in our prospective exertional myalgia study some MAD-deficient 
cases remained undetected due to a low sensitivity of the screening-test. However, 
as previously described,20 this is highly unlikely. 
2. the threshold for patients to be selected for muscle biopsy is higher than for 
exercise testing. So, possibly, in our prospective exertional myalgia group more 
patients have been included with a.o. complaints of psychogenic origin, than in the 
retrospective muscle biopsy group of Kelemen et al.," which lowers the frequency 
of occurrence of MAD-deficiency in the prospective study. 
3. MAD-deficiency is rather often associated with a moderate CK-clevation.4 It is not 
impossible that in the selection of patients for muscle biopsy in Kelemcn's study 
this elevation has played a role and thus his exertional myalgia group might be 
enriched with MAD-deficiency. In our selection for exercise testing this CK-
elevation did not play a role. 
4. children do not often complain explicitly of exertional myalgia. So the inclusion of 
children in the reference muscle biopsy group of Kelemen et al. might be a cause of 
distortion of the prevalence figures. 
Summarizing the data, there is for the moment no statistically significant evi-
dence that MAD-deficiency is seen more often in exertional myalgia, the supposed 
clinical syndrome of MAD-deficiency. If there is a relation between MAD-deficiency 
and exertional myalgia, then this concerns only a minority of the MAD-deficient cases 
as is evident from the discovery of only 2 deficient symptomatic relatives out of 8 
deficient relatives in a family survey21. Therefore in many cases MAD-deficiency 
seems to be a harmless genetic variant. 'I he question of the clinical relevance of M AD-
deficiency still awaits a better understanding of the physiologic and metabolic con-
sequences of the deficiency. 
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CONCLUDING REMARKS 
In this study we have tried, as outlined in Chapter I, to answer some questions 
that have arisen with regard to a recently described new enzyme deficiency of skeletal 
muscle· myoadenylate deaminase deficiency.' 
The lack of a strongly suggestive set of clinical signs or symptoms and the supposed 
high frequency of occurrence made it necessary to refine the screening method 
originally suggested by Fishbein. ' Because it was early recognized that the main source 
of the ammonia produced during exercise was the reaction catalyzed by myoadenyl-
ate deaminase (MAD),2 the plasma determination of ammonia (together with lactate, 
as an independent estimate of the intensity of muscular work), constitutes the pillar of 
the screening method. 
Chapters II and III deal with the questions which force level and frequency of 
contractions should result in blood concentrations of lactate and ammonia that 
discriminate between patients and controls, and whether standardization of the 
ischaemic exercise test would improve screening in MAD-deficiency. 
Up to now a major problem in interpreting the results of ischaemic exercise tests 
has been the assessment whether the subject performed sufficient work. Help in 
determining if sufficient work has been performed during the ischaemic test comes 
from studies, documenting a linear relationship between increases in ammonia and 
lactate during exercise in normal subjects.'1 s In case there is a subnormal elevation of 
lactate as well as of ammonia, it is now possible, with the concurrent measurement of 
lactate and ammonia and because of this linear relationship, to denote an inadequate 
work-performance. By measuring only lactate, as McArdle6 did, it was not possible to 
differentiate between a glyco(geno)lytic defect or just an insufficient work-perfor-
mance. Thus the concurrent measurement of lactate and ammonia levels during 
ischaemic exercise performance should be of considerable assistance in evaluating 
patients suspected to have a metabolic disorder of muscle function as. (1) it can help 
establish whether the work performed was an adequate challenge for the 
glyco(geno)lytic pathway or the purine nucleotide cycle (PNC), and (2) it has poten-
tial to identify patients with metabolic disorders that may present the symptoms of 
exertional myalgia (e.g. MAD-deficiency, McArdlc's disease). Our study shows that 
standardization improves screening in MAD-deficiency, but we do not pretend to 
have arrived at the optimal challenge for the PNC of which AMP deamination is one 
step. Although most arguments are in favour of maximal enzyme activity during 
ischaemic exercise,7 " there is one proposed function of the PNC that does not come 
into play under ischaemic conditions. This is the production of fumarate, an inter-
mediate of the oxydative citric acid cycle.10 Iherefore, it is imaginable that the 
consequences of MAD-deficiency arc shown most prominently when muscles are 
exercising under more or less aerobic conditions. In this case a non-ischaemic test 
device would deserve attention. Nevertheless, the standardized ischaemic forearm test 
has been shown to be a very sensitive screening method in MAD-deficiency. 
The supposed pathophysiological consequences of MAD-deficiency might be 
associated with a disruption of the PNC. ' ' Several mechanisms have been suggested to 
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explain the role of the PNC in skeletal muscle:' ш 
1. the increase of the flux through the PNC could serve to maintain the energy-charge 
(EC) during muscular contraction; 
2. the ammonia production might stimulate phosphofructokmase and enhance the 
rate of glycolysis; 
3. the PNC could serve to replenish fumarate, a citric acid cycle intermediate, which 
might be important during an increased demand for ATP; 
4. the accumulation of IMP during exercise might preserve the skeletal muscle purine 
nucleotide pool by preventing the degradation of AMP to adenosine, inosine and 
hypoxanthine. 
The measurements of several metabolites in plasma (chapter IV) and muscle biopsies 
(chapter V) from MAD-deficient patients throw some light on these proposed mecha­
nisms. 
ad 1. disruption of the PNC caused by MAD-deficiency does not result in an inability 
to maintain the EC at a normal level during ischaemic isometric exercise. 
ad 2. the reduced production of ammonia in MAD-deficiency does not prevent the 
normal stimulation of glyco(geno)lysis as shown by the skeletal muscle lactate 
concentrations after exercise. 
ad 3. the effect of a reduced fumarate generation on the ATP production of MAD-
deficicnt muscle can probably not be studied under ischaemic, i.e. anaerobic 
conditions such as in our test because, as mentioned before, fumarate can only 
serve as a fuel when oxygen is available. 
ad 4. the hypothesis that IMP accumulation during muscular contraction preserves 
the purine nucleotide pool is not supported by the finding in MAD-deficient 
patients of an elevated skeletal muscle total adenine nucleotide content and a 
subnormal increase of plasma inosine and hypoxanthine after exercise. 
The results of the studies described in chapter IV and chapter V have not 
provided any evidence of how the disruption of the purine nucleotide cycle might 
cause the symptoms of exertional myalgia. In view of the very high skeletal muscle 
MAD-activity, however, it is quite possible that MAD has a certain as yet unrecog­
nized function which may or may not be associated with the PNC. Perhaps future 
studies on MAD-deficiency will reveal this function. 
Finally, chapter VI and chapter VII deal with the question whether MAD-
deficiency manifests itself with exertional myalgia or not. In solving this problem two 
approaches have been used First, the relatives of known MAD-defiuent patients were 
screened for MAD-dcficicncy after they had completed a questionnaire on exercise-
related complaints. In this way 8 new MAD-deficient subjects were discovered of 
whom only 2 complained explicitly of exertional myalgia. This means that probably 
only a minority of MAD-deficient individuals in the population will complain of 
exertional myalgia. Additionally, it became evident that MAD-deficiency shows an 
autosomal recessive mode of inheritance. The findings pointed to a high frequency of 
heterozygotes in the general population. 
In the second approach, the frequency of occurrence of MAD-deficiency m a 
92 
series of muscle biopsies executed because of not exercise-related complaints, was 
compared with the prevalence found m a patient cohort with exercise-related com­
plaints. Although the frequency of occurrence of MAD-deficiency is higher in the 
exertional myalgia group than in the muscle biopsy series, the difference does not 
reach the level of significance. This is in disagreement with the findings of Kelemen et 
al.12 However, as evidenced in chapter VII there are many questions unresolved 
concerning the findings of Kelemen et al. We are convinced that for the moment there 
is no evidence for a relation between exertional myalgia and MAD-deficiency. It is 
possible that MAD-deficiency does not produce symptoms unless in concert with 
other, as yet unknown abnormalities or circumstances. Such an abnormality could be, 
for instance, an altered fiber-type distribution in MAD-deficicncy. The finding of the 
highest activity of MAD in type IIВ fibers13 and type II fiber predominance in muscle 
cramp and exertional myalgia1'' both point to this possibility. In the study described in 
chapter V all controls (N = 10) and symptomatic patients (N = 5) were biopsied. 
Analysis of variance, however, revealed no significant difference (P > 0.05) between 
controls and patients in relation to fiber-type distribution. 
Until now we have not commented on the frequent association of MAD-deficien-
cy with other neuromuscular disorders and on the subsequent question whether this 
association is simply coincidental, or occurs as a consequence of the neuromuscular 
disorder. In this context a primary form of MAD-deficiency means a coincidental 
association of MAD-deficiency with other neuromuscular diseases whereas a second­
ary form of MAD-deficiency refers to the deficiency-state being the consequence of 
another disorder. bishbeinh states that there is definitely a secondary form of MAD-
deficiency, m which all of the muscle enzymes are lowered by pathologic damage, but 
adenylate deaminase is lowered out of proportion to the others. This statement is 
based on the following facts: (1) an associated muscle disease is much more likely in 
patients with a high residual MAD-activity, or, in other words, the lower your 
residual enzyme activity, the more likely you are to have pristine deficiency with no 
other neuromuscular pathology; and (2) the residual MAD-activity in secondary 
cases shows significant, although incomplete, removal by antibody, whereas, rabbit 
antisera to the purified human skeletal muscle isozyme do not react with the residual 
adenylate deaminase activity of primary deficient muscle biopsies.16 
When the first strategy is applied to our material i.e. when the cases of MAD-
deficiency are sorted according to their residual MAD-activity, we do find associated 
neuromuscular disorders in patients with low residual MAD-activity (Table 1). This 
points to chance association of MAD-deficiency with other neuromuscular diseases 
and probably to a high prevalence of MAD-deficiency not only in muscle biopsy series 
but also in the general population. So our results do not show the relation between 
associated neuromuscular pathology and the high residual enzyme activity as re­
ported by Fishbein.n 
When considering all previous findings, it cannot be ruled out that MAD-
deficiency is only a harmless, frequently occurring genetic curiosity without exercise-
related symptoms. Nor do we consider an altered purine metabolism, as exists in 
MAD-deficiency )udging by the plasma-hypoxanthine concentration and purine-
nucleotide content of muscle after exercise, to explain the complaints. A better 
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understanding of the metabolic and physiological consequences of the deficiency will 
probably bring the clinical relevance of the deficiency in some cases to evidence. 
Table I. MAD-deftctent subjects sorted according to their residual adenylate deaminase activity. 
Patient number Clinical finding or Histopathology Residual MAD activity 
(% control mean) 
<0.S 
<o.s 
< 0.5 
<0.5 
< 0.5 
<o.s 
< 0.5 
<0.5 
< 0.5 
< 0.5 
< 0.5 
<0.5 
<0.4 
< 0.5 
0.6 
0.8 
0.9 
0.9 
0.9 
1.1 
1.2 
1.3 
1.3 
1.7 
1.8 
2.0 
3.8 
4.0 
6.2 
6.9 
15.7 
2. 
4. 
6. 
7. 
11. 
16. 
18. 
21. 
22. 
28. 
31. 
13 
34. 
36. 
30. 
10. 
37. 
13. 
25. 
17. 
26. 
3. 
1. 
5. 
12. 
14. 
24. 
23. 
15. 
20. 
9. 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional myalgia 
neuropathy 
neuropathy 
neuropathy 
neuropathy 
none 
none 
none 
none 
none 
exertional myalgia 
none 
neuropathy 
muscular dystrophy 
neuropathy 
muscular dystrophy 
exertional myalgia 
exertional myalgia 
exertional myalgia 
exertional myalgia 
acid maltase deficiency 
muscular dystrophy 
muscular dystrophy 
myotonic dystrophy 
neuropathy 
exertional myalgia 
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APPENDIX 
Several case-studies are presented with the intent to illustrate (1) the supposed 
clinical picture of MAD-deficiency (case 1 and 2), (2) the difficulty in some cases to 
define the limits of exertional myalgia and to impute muscle fatigue to MAD-
deficiency (case 3) and (3) the association of MAD-deficiency with other neuromuscu­
lar disorders (case 4 and 5). 
All the patients in this study are listed in Table 1. 
Table 1 
MAD-defiuency with the dimeni feature of exertional mvalgia 
Patient 
number 
1. 
2. 
3. 
4. 
5 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
MAD-def 
Patient 
number 
13 
14. 
15. 
16. 
17. 
18. 
19. 
20 
21. 
22. 
Sex 
M 
F 
F 
M 
M 
M 
M 
M 
F 
M 
M 
M 
'taency wi 
Sex 
M 
M 
M 
M 
M 
M 
l· F 
M 
M 
Age at time ol 
of complaints 
25 
12 
3 
37 
42 
16 
8 
S 
14 
13 
31 
12 
onset CK 
(yrs) 
39 
18 
34 
132 
44 
47 
161 
101 
и 
П 4 
58 
109 
Residual MAD activity 
(% control mean) 
1 3 
0.5 
1.3 
0.5 
1.7 
0.5 
0.5 
N.D 
15.7 
0.8 
0.5 
1.8 
ith an associated neuromuscular disorder and exertional myalgia 
Age at time 
of diagnosis 
(yrs) 
68 
34 
36 
5} 
58 
57 
15 
52 
12 
60 
CK 
37 
178 
540 
94 
67 
84 
496 
39 
164 
42 
Histopathology 
neuropathy 
acid maltase defic. 
myotonic dystrophy 
focal motor neuron loss 
neuropathy 
neuropathy 
myotonic dystrophy 
neuropathy 
neuropathy 
neuropathy 
Residual MAD activity 
(% control mean) 
0.9 
2 0 
6.2 
0.5 
1 1 
0 5 
N.D. 
6.9 
0.5 
0.5 
CK value normal, less than 100 U/l. 
N.D. = not determined 
MAD-deftaency with an associated neuromuscular disorder without known exertional myalgia 
Patient Sex Age at time CK Histopathology Residual MAD activity 
of diagnosis (% control mean) 
(yrs) 
number 
23. 
24. 
25. 
26. 
27. 
28. 
29 
M 
M 
M 
M 
M 
M 
F 
0 
7 
3 
2 
0 
4 
69 
68 
6110 
155 
3000 
76 
96 
943 
cong. dystrophy 
dystrophy 
dystrophy 
dystrophy 
cong. dystrophy 
neuropathy 
myosins 
4.0 
3.8 
0.9 
1.2 
N D 
0.5 
N.D. 
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MAD-defiaency without an associated neuromuscular disorder or exertional myalgia 
Patient number Sex 
30 M 
31 F 
32 M 
33 M 
34 Ь 
35 M 
36 M 
37 M 
38 M 
39 M 
40 M 
41 M 
Age at time of 
diagnosis (yrs) 
2 
11 
51 
17 
14 
43 
13 
34 
47 
42 
25 
29 
CK 
85 
46 
29 
279 
52 
127 
52 
112 
N D 
N D 
104 
86 
Residual MAD activity 
(% control mean) 
0 6 
0 5 
N D 
0 5 
0 5 
N D 
0 5 
0 9 
N D 
N D 
N D healthy volunteer 
N D healthy volunteer 
CASE REPORTS 
1. Patient no 1 
A 32-year-old man was the second child of non-consanguineous parents. He was 
referred in 1982 with complaints of generalized muscle aches after exertion since 3 
years. Before that time he could run a marathon without great difficulties but 
nowadays, he stated to 'hit the wall' about half-way. He noticed a slight progression 
of the complaint and also that chewing caused aching of the jaw muscles. His history 
gave no evidence of a second wind phenomenon or pigmentuna. The only and elder 
sister of the patient was more severely disabled by having complaints already when 
climbing a flight of stairs. In the family-study (chapter VI) she also appeared to be 
MAD-deficient. 
Physical examination nor routine chemical blood- and urine analysis of this male 
revealed any abnormality. A right quadriceps muscle biopsy specimen showed no 
abnormalities except for the absence of histochemical MAD-activity. 
Conclusion: familial coincidence of exertional myalgia with MAD-deficiency. 
2. Patient no 10 
This 26-year-old man came to medical attention when aged 21 years because of a 
progressive exercise-intolerance which he suffered from since childhood. As an 
amateur motor-crosser he experienced soreness and stiffness in both his forearms 
during races, especially when the weather was cold. They were relieved in half an hour 
of rest. His history gave no evidence of pigmentuna; there was no family-history of 
any muscle disease. 
Clinical examination revealed no abnormalities, blood examination repeatedly 
showed mildly elevated plasma creatine kinase levels (134-168 U/1; normal values up 
to 100 U/1). An EMG showed the presence of some small polyphasic potentials of 
short duration. In a right quadriceps muscle biopsy specimen the absence of MAD-
staming was demonstrated but showed otherwise no abnormalities. 
Conclusion: lifelong exertional myalgia. 
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3. Patient no. S 
A 50-year-old man was hospitalized at age 46 for severe and permanent muscle-
aches in the left lower-leg. He experienced an exercise-induced progression of this 
complaint. 
On examination, muscle bulk was normal and there was no weakness at rest. The 
lumbar spine functioned without abnormal findings. Blood examination revealed no 
abnormalities, an EMG showed no evidence of nerve entrapment. X-ray studies 
showed a first degree hsthesis of L5 with the lumbar sub-arachnoideal space having a 
diameter just within normal limits. Except for absent adenylate deaminase staining, a 
biopsy of the left gastrocnemius muscle was normal. 
Conclusion: (pseudo) radicular syndrome or MAD-deficicncy5 
4. Patient no. 18 
This 59-year-old male was referred in 1983 with suspicion of a neuropathy. He 
complained of progressive and painful paraesthesia of both feet since 1982. He also 
had, however, a 20-year history of easy fatiguability and leg pains induced by 
exercise. The patient ascribed these complaints to a myocardial infarction in 1964. 
Physical examination was normal except for decreased sensibility in both lower-
legs. EMG and nerve conduction studies were consistent with an axonal polyneuropa-
thy. A left sural nerve biopsy specimen showed a decrease in myelinated fibers 
whereas a left soleus muscle biopsy showed type-grouping and sporadic nuclear 
aggregation with mild endomysial connective tissue proliferation. The MAD-staining 
was absent. 
Conclusion: primary MAD-deficiency together with a polyneuropathy. 
5. Patient no. 29 
A 70-year-old woman had suffered from a stiff back and muscle weakness of the 
arms for 8 months. Besides, she noticed an aching discomfort in her shoulders. 
Physical examination showed no abnormalities except for a mild generalized 
muscle weakness. Scrum-transaminase, LDH and CK were elevated and suggested a 
polymyositis which was confirmed in a quadriceps muscle biopsy specimen. MAD-
staining was absent. 
Conclusion: polymyositis with absent MAD-staining and without exertional 
myalgia. 
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SUMMARY 
This thesis deals with the investigation into an enzyme deficiency in muscle which 
has only recently been described but has, nevertheless, a high prevalence: myoadenyl-
ate deaminase deficiency. This enzyme deficiency is often associated with complaints 
of aching muscles, muscle spasm, and abnormal fatiguabihty due to physical exertion, 
commonly denoted as exertional myalgia. The results of this study are laid down in six 
papers discussing the following three aspects of the disease: 
— the screening for the deficiency, avoiding the necessity of a biopsy, 
— the biochemical changes during exercise that might account for the complaints, 
— the clinical significance of the deficiency. 
The aim of chapter I is to outline the framework from which the questions, 
formulated at the end of the chapter, originate. It contains a description of the 
conflicting opinions found in literature as to the deficiency's clinical significance. The 
conflict is based on the absence of a specific pattern of complaints and on the fact that 
the enzyme deficiency is often an incidental, secondary finding in other neuromuscu-
lar disorders. The enzyme's place as a part of the purine nucleotide cycle is discussed, 
as well as the relevance of this cycle for the energy economy within the muscle and its 
consequences for the development of the screening methodology. We decided to use 
the ischaemic forearm test in combination with measurement of lactate and ammonia 
levels before and after exertion. The main source of ammonia during muscular 
exertion is the ammonia freed in the conversion of AMP into IMP by the enzyme 
which is the focus of this study: myoadenylate deaminase. Lactate is measured 
because it serves as an independent variable for the muscle exertion performed. Next, 
the various views on the mode of inheritance are dealt with. Hnally, the objectives of 
the study are worded in six questions, the answers to which arc given in the following 
chapters. 
Chapter II describes the search (by means of an ischaemic forearm test) for the 
combination of strength and frequency resulting in the highest possible lactate and 
ammonia levels. A frequency of 30 isometric contractions per minute with a voluntary 
contraction force of 80% of the maximal strength has turned out to be the combina-
tion producing the best results. 
Chapter III is about the comparison of specificity and sensitivity of this standard-
ized test and a not-standardized one, with regard to the detcctibihty of the enzyme 
deficiency. Furthermore the different ways of plotting the results of the standardized 
test are compared, in order to be able to discriminate between deficient and not 
deficient individuals. Surprisingly, deficient individuals have proved to be able to 
perform the same amount of 'work' in these exercise tests as healthy volunteers. 
In chapter IV the measurements are stated of a number of purine nucleotide 
degradation products in venous blood of healthy volunteers and patients. These 
measurements have been carried out before as well as after the individuals performed 
the standardized ischaemic forearm test. It is apparent that patients with enzyme 
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deficiency produce considerably fewer degradation products of AMP (inosine and 
hypoxanthine). From this it is concluded that the alternative route of removing AMP 
from the deficient muscle by conversion into adenosine is not used to a large extent in 
this test. 
Chapter V deals with the changes in the tissue concentrations of energy-rich 
compounds before and after an isometric contraction of the quadriceps muscle. 
Measurements in enzyme-deficient patients and healthy volunteers show that there 
are no differences between both groups as to (1) the work-performance and (2) the 
amount of energy used per unit of work. This implies that by means of an ischaemic 
isometric test it cannot be demonstrated that the enzyme-deficient patient is at 
disadvantage compared to a healthy person as far as his energy economy is concerned. 
Yet in the deficient group, both before and after exercise, purine nucleotide con-
centrations, with the exception of AMP, are higher than those in the volunteers. 
Neither chapter III, nor chapters ƒ V and V provide evidence of some disorder in 
the purine nucleotide cycle which might explain the clinical symptomatology usually 
associated with the deficiency. 
Chapter VI enters into the clinical and genetic aspects of the enzyme-deficiency 
by means of a family survey. Thirty-six relatives of 9 probands are examined for a 
possible deficiency with the aid of the standardised ischaemic exercise test. 
Eight new deficient relatives are discovered, only 2 of whom, however, have 
exercise-related complaints. This finding casts doubt on the enzyme-deficiency's 
clinical significance regarding exercise-related complaints. The data obtained from 
the survey are in accordance with an autosomal recessive inheritance. 
In chapter VII the question of the deficiency's clinical significance is approached 
by way of determining the enzyme-deficiency's prevalence in three different patient 
populations and comparing the results. Prevalence was established in: (1) a routine 
series of muscle biopsies, carried out to diagnose a variety of neuromuscular disorders 
with the exception of biopsies done on account of exertional myalgia, (2) a patient 
cohort just because of their exercise-related complaints, as this is the presumed 
clinical syndrome in the enzyme deficiency. This group of patients was examined by 
means of the standardized ischaemic exercise test. In cases where the tests suggested a 
MAD-deficiency a muscle biopsy was performed in order to corroborate this, (3) a 
group of healthy volunteers, also by means of the screening test mentioned before. 
Comparison of the different prevalences showed that the deficiency does not 
have a statistically significant higher prevalence in the group of patients with exercise-
related complaints, and that it also occurs in a group without complaints. 
Finally, in chapter VII we comment on the functions of the purine nucleotide 
cycle as they are described in literature but do not seem to be confirmed by the findings 
of our own investigations. Moreover, the chapter goes into the association of the 
enzyme-deficiency with other neuromuscular diseases, which we consider to be based 
mainly on coincidence and it is not secondary to the primary disease. 
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We have come to the conclusion that myoadenylate deaminase deficiency is a 
frequently occurring, harmless genetic variant, which does not necessarily induce 
exercise-related complaints. 
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SAMENVATTING 
Dit proefschrift omvat het onderzoek naar een eerst onlangs (1978) beschreven 
maar veelvuldig voorkomende cnzym-deficientie in skeletspieren: de myoadenylaat 
deaminase deficiëntie. Deze enzym-deficientie wordt in verband gebracht met 'exer-
tional myalgia', klachten over spierpijn, spierkramp en abnormaal snelle vcrmoei-
baarheid ten gevolge van inspanning. De zes artikelen waarin de resultaten van deze 
studie hun neerslag vinden, hebben betrekking op een drietal aspecten van de aandoe-
ning, te weten: 
- de screening op de aanwezigheid van de deficiëntie zonder dat een biopt noodzake-
lijk is, 
- de biochemische veranderingen tijdens inspanning die de klachten ¿ouden kunnen 
verklaren, 
- de klinische betekenis van de deficiëntie. 
Hoofdstuk I beoogt het kader aan te geven van waaruit de aan het eind van het 
hoofdstuk geformuleerde vragen, zijn ontstaan. Het beschrijft de tegengestelde me-
ningen welke in de literatuur bestaan ten aanzien van de klinische betekenis van de 
deficiëntie doordat er ten eerste, geen specifiek klachtenpatroon aanwezig is, en ten 
tweede, het ontbreken van het enzym herhaaldelijk een bijkomende bevinding is bij 
neuromusculairc aandoeningen. Besproken worden de plaats van het enzym in de 
purine nucleotide cyclus en het belang van deze cyclus voor de energie-huishouding 
van de spier met de daaruit voortvloeiende consequenties voor de te ontwikkelen 
screenings-methodiek. Gekozen wordt voor een gestandaardiseerde ischaemische 
handknijptest met lactaat en ammomakbepalingen vóór en na inspanning. De belang-
rijkste bron van ammoniak tijdens spierinspanning is het ammoniak dat gevormd 
wordt bij de omzetting van AMP naar IMP door het enzym dat centraal staat in dit 
onderzoek: het myoadenylaat deaminase (MAD). Lactaat wordt gemeten omdat het 
dient als een onafhankelijke resultante van de verrichte spierinspanning. Hierna 
komen een aantal onduidelijkheden ter sprake betreffende de wijze van overerven. 
Tot slot worden de doelstellingen van het onderzoek beschreven welke zijn vervat in 
een zestal vragen waarvan de beantwoording plaatsvindt in de successievelijke hoofd-
stukken. 
In hoofdstuk II wordt het zoeken, met behulp van een ischaemische handknijp-
test, beschreven naar die combinatie van kracht en frequentie waarmee de hoogste 
lactaat- en ammoniakwaarden verkregen kunnen worden. Een frequentie van 30 
isometrische contracties per minuut met een krachtsniveau van 80% van de maximale 
kracht blijkt de combinatie welke leidt tot de hoogste waarden. 
Hoofdstuk III is gewijd aan de vergelijking van de specificiteit en sensitiviteit van 
deze gestandaardiseerde en niet-gcstandaardiseerde testopstelling met betrekking tot 
de mogelijkheid om de enzym-deficientie vast te stellen. Tevens worden de verschil-
lende wijzen waarop de uitkomsten van de gestandaardiseerde test kunnen worden 
uitgezet vergeleken, teneinde zo goed mogelijk te kunnen discrimineren tussen defi-
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cienten en niet-deficienten. Verrassenderwijze blijken deficienten tijdens deze inspan-
ningstest evenveel 'arbeid' te kunnen verrichten als gezonde proefpersonen. 
In hoofdstuk IV worden de bepalingen vermeld van een aantal purine nucleotide 
degradatieproducten in veneus bloed bij gezonde proefpersonen en patiënten. Deze 
metingen worden verricht zowel vóór als na het uitvoeren van de gestandaardiseerde 
ischaemische handknijptest. Het blijkt dat patiënten welke enzym-deficient zijn, 
beduidend minder afbraakproducten van AMP (inosine en hypoxanthine) produce-
ren. Hieruit wordt geconcludeerd dat de alternatieve mogelijkheid om de AMP 
concentratie te verlagen via de omzetting in adenosine in de deficiente spier bij deze 
testopstelling niet in belangrijke mate gebruikt wordt. 
In hoofdstuk V worden de veranderingen behandeld in de spierweefsel-concen-
traties van AMP, ADP, ATP, CP en lactaat vóór en na een isometrische contractie van 
de musculus quadriceps. De metingen bij enzym-deficienten en gezonde proefperso-
nen maken duidelijk dat er geen verschillen bestaan tussen de beide groepen wat 
betreft (1) de geleverde inspanning en (2) de hoeveelheid verbruikte energie per 
eenheid van inspanning. Dit wil dus zeggen dat met deze ischaemische, isometrische 
test-opstelhng niet aangetoond kan worden dat de enzym-deficiente patient wat 
betreft zijn energie-huishouding in het nadeel is ten opzichte van gezonde proefperso-
nen. Evenwel zijn in de deficiente groep de concentraties purine-nucleotiden, met 
uitzondering van AMP, zowel vóór als na de inspanning hoger dan bij de proefperso-
nen. 
Zowel in hoofdstuk Hl als in hoofdstuk ¡Ven Vworden geen aanwijzingen gevonden 
voor een ontregeling van de energie huishouding die de klinische Symptomatologie, 
welke gewoonlijk aan de deficiëntie wordt gekoppeld, zou kunnen verklaren. 
In hoofdstuk VI wordt ingegaan op de klinische- en genetische aspecten van de 
enzym-deficientic aan de hand van familie-onderzoek. 36 Verwanten van 9 probandi 
worden met behulp van de gestandaardiseerde ischaemische inspannings-test onder-
zocht op de mogelijkheid van vóórkomen van de deficiëntie. 
Er worden 8 nieuwe deficienten ontdekt waarvan er echter maar 2 inspannings-
gebonden klachten hebben. Deze bevinding doet twijfel ontstaan aan de klinische 
betekenis van de enzym-deficientic voor wat betreft de aan inspanning gerelateerde 
klachten. De uit de studie verkregen gegevens zijn in overeenstemming met een 
autosomaal-recessieve erfgang. 
In hoofdstuk VII wordt de vraag naar de klinische betekenis van de deficiëntie 
benaderd door in een drietal populaties de prevalentie voor deze enzym-deficientie te 
bepalen en met elkaar te vergelijken. De prevalenties zijn nagegaan: (1) in een routine 
serie spierbiopten welke zijn verricht voor de diagnostiek van een aantal neuromuscu-
laire aandoeningen, met uitzondering van die biopten welke verricht werden alleen 
vanwege 'exertional myalgia', (2) in een patiënten-cohort met juist dergelijke aan 
inspanning gerelateerde klachten omdat dit het veronderstelde klachtensyndroom is 
bij de enzym-deficientie. Deze patiëntengroep werd onderzocht met de gestandaardi-
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scerdc ischaemische inspannmgstest. Indien deze test wees op een MAD-deficientie 
dan werd ter bevestiging een spierbiopsie verricht en (3) in een groep gezonde 
proefpersonen eveneens met behulp van de eerder vernoemde screenings-test. 
Vergelijking van de verschillende prevalenties leert ons dat de deficiëntie met 
statistisch significant méér frequent aanwezig is in de groep met aan inspanning 
gebonden klachten en dat de deficiëntie ook in een groep zonder klachten voorkomt. 
In hoofdstuk Ш tenslotte worden een aantal kanttekeningen geplaatst bij de in 
de literatuur veronderstelde functies van de purine nucleotide cyclus welke door onze 
onderzoeksbevindingen met bevestigd worden. Het gaat tevens in op het samengaan 
van de enzym-deficientie met andere neuromusculaire aandoeningen, hetgeen ons 
inziens veelal berust op toeval en met secundair is aan de primaire aandoening. 
Wij komen tot de conclusie dat de myoadenylaat deaminase deficiëntie een 
veelvuldig voorkomende, onschuldige genetische variant is welke met noodzakelij-
kerwijze leidt tot aan inspanning gebonden klachten. 
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STELLINGEN 
behorende bi] het proefschrift 
MYOADENYLATE DEAMINASE DEFICIENCY 
I 
De afwezigheid van klachten bij personen die myoadenylaat deaminase deficient 
blijken te zijn, noopt ertoe de betekenis van de purine nucleotide cyclus voor de 
skeletspier tijdens inspanning aan een herbeschouwing te onderwerpen. 
II 
Bij myoadenylaat deaminase deficiëntie is het onwaarschijnlijk dat tijdens inspanning 
een abnormale toename van de bloeddoorstroming in de spieren optreedt. 
III 
De betekenis van het tijdens inspanning middels oppervlakte electroden geregistreer-
de myogram voor het inzicht in de pathofysiologie van 'exertional myalgia', wordt 
onvoldoende gewaardeerd. 
IV 
Bij het onderzoek naar de oorzaak van inspanningsgebonden klachten dient betrok-
ken te worden in hoeverre de klachten een gevolg kunnen zijn van een slechte 
lichamelijk conditie respectievelijk trainingstoestand. 
V 
Resectie van de eerste rib als therapie voor een 'thoracic outlet' syndroom wordt 
veelal ten onrechte toegepast. 
VI 
De dementie geassocieerd met de ziekte van Parkinson wordt waarschijnlijk veroor-
zaakt door een stoornis in meerdere neurotransmitter systemen. 
VII 
Het bezigen van de uitdrukking 'vlucht in de waanzin' ter verklaring van sommige 
psychosen veronderstelt ten onrechte wilsvrijheid. 
VIII 
De verscheidenheid aan psychopathologie van verschillende en gewaardeerde schrij-
vers doet vermoeden dat de waardering wel samenhangt met hun psychopathologie 
maar met gebonden is aan één specifieke vorm. 
IX 
Het primaat van het lichaam in de fraaie versregels uit SlauerhofPs gedicht 'Het 
boegbeeld· de ziel': 
Dtt is mijn lot: gebeeldhouwd voor den boeg, 
Den scheepsromp achter mi] te moeten volgen; 
brengt de dialectische wederkerigheid van lichaam en ziel op een niet gebruikelijke 
wijze uit balans. 
X 
'It is better to travel hopefully than to arrive'. 
S. P. T. Sinkeier Langenboom, 23 januari 1987 



